Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
23,100 | 2022-09-29 00:00:00 UTC | Noteworthy ETF Inflows: XLV, ABBV, MDT, ELV | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-xlv-abbv-mdt-elv | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $179.6 million dollar inflow -- that's a 0.5% increase week over week in outstanding units (from 3... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 1.1%, Medtronic PLC (Symbol: MDT) is down about 1.1%, and Elevance Health Inc (Symbol: ELV) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ET... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 1.1%, Medtronic PLC (Symbol: MDT) is down about 1.1%, and Elevance Health Inc (Symbol: ELV) is lower by about 0.3%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year p... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 1.1%, Medtronic PLC (Symbol: MDT) is down about 1.1%, and Elevance Health Inc (Symbol: ELV) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ET... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 1.1%, Medtronic PLC (Symbol: MDT) is down about 1.1%, and Elevance Health Inc (Symbol: ELV) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ET... |
23,101 | 2022-09-28 00:00:00 UTC | Where to Invest $10,000 Right Now | ABBV | https://www.nasdaq.com/articles/where-to-invest-%2410000-right-now | null | null | It isn't an easy market for investors right now. Prolonged periods of volatility along with dips near or even into bear market territory have become commonplace for investors in recent months as fears of a looming recession, geopolitical headwinds, and ongoing concerns about the global economy continue to remain front ... | As sales of Humira give way to generic competition both domestically and abroad as the drug loses U.S. patent exclusivity in 2023, AbbVie has plenty of other products to fall back on. AbbVie Healthcare stocks had quite the heyday in the early pandemic, when investors were rushing to put their cash into any and all comp... | AbbVie Healthcare stocks had quite the heyday in the early pandemic, when investors were rushing to put their cash into any and all companies in this space. AbbVie (NYSE: ABBV) is a prime example of a healthcare stock you can buy and hold for years. As sales of Humira give way to generic competition both domestically a... | Not only is AbbVie a Dividend King, but its consistent dividend and share price growth has resulted in the stock delivering a total return of 40% over the past year alone. AbbVie Healthcare stocks had quite the heyday in the early pandemic, when investors were rushing to put their cash into any and all companies in thi... | Not only is AbbVie a Dividend King, but its consistent dividend and share price growth has resulted in the stock delivering a total return of 40% over the past year alone. AbbVie Healthcare stocks had quite the heyday in the early pandemic, when investors were rushing to put their cash into any and all companies in thi... |
23,102 | 2022-09-27 00:00:00 UTC | 2 High-Yielding Dividend Stocks That Could Raise Their Payouts in October | ABBV | https://www.nasdaq.com/articles/2-high-yielding-dividend-stocks-that-could-raise-their-payouts-in-october | null | null | An increase in a quarterly dividend payment is something all income investors love to hear about. That's because it means they're collecting more money from their investments. For example, if a stock were to increase its dividend by 3% each year, it would amount to an increase of over 34% over a 10-year period, thanks ... | News of a dividend increase in October could bolster the stock higher, especially if AbbVie also reports some solid quarterly results. Two stocks that have been raising their payouts for decades are AbbVie (NYSE: ABBV) and ExxonMobil (NYSE: XOM). AbbVie Drugmaker AbbVie pays a high dividend yield of around 4% per year. | Through the first six months of this year, AbbVie's sales totaled $28.1 billion and increased 4.3% year over year. Two stocks that have been raising their payouts for decades are AbbVie (NYSE: ABBV) and ExxonMobil (NYSE: XOM). AbbVie Drugmaker AbbVie pays a high dividend yield of around 4% per year. | Through the first six months of this year, AbbVie's sales totaled $28.1 billion and increased 4.3% year over year. Two stocks that have been raising their payouts for decades are AbbVie (NYSE: ABBV) and ExxonMobil (NYSE: XOM). AbbVie Drugmaker AbbVie pays a high dividend yield of around 4% per year. | Two stocks that have been raising their payouts for decades are AbbVie (NYSE: ABBV) and ExxonMobil (NYSE: XOM). AbbVie Drugmaker AbbVie pays a high dividend yield of around 4% per year. What's more, AbbVie is a Dividend King and has raised its payouts annually for 50 consecutive years. |
23,103 | 2022-09-27 00:00:00 UTC | Is Loading Up on Passive Income Stocks Right Now a Good Idea? | ABBV | https://www.nasdaq.com/articles/is-loading-up-on-passive-income-stocks-right-now-a-good-idea | null | null | Many investors dream of building a portfolio that delivers significant passive income. If you invest your funds carefully, that dream is always within reach, and now's a very tempting time to make progress toward it.
With a bear market in full swing, there are undoubtedly more buying opportunities as stocks look seemin... | Therefore, investors should seriously consider buying shares of high-quality passive income stocks like AbbVie whose distributions are secure in light of the economic headwinds that they can reasonably expect to encounter. In particular, profitable and growing pharmaceutical businesses like AbbVie (NYSE: ABBV) are like... | In particular, profitable and growing pharmaceutical businesses like AbbVie (NYSE: ABBV) are likely to be resilient in the face of the current set of headwinds. As AbbVie generated nearly $22 billion in free cash flow (FCF) in 2021 while paying only around $9.2 billion in dividends, it's clear that there's plenty of ro... | In particular, profitable and growing pharmaceutical businesses like AbbVie (NYSE: ABBV) are likely to be resilient in the face of the current set of headwinds. As AbbVie generated nearly $22 billion in free cash flow (FCF) in 2021 while paying only around $9.2 billion in dividends, it's clear that there's plenty of ro... | In particular, profitable and growing pharmaceutical businesses like AbbVie (NYSE: ABBV) are likely to be resilient in the face of the current set of headwinds. As AbbVie generated nearly $22 billion in free cash flow (FCF) in 2021 while paying only around $9.2 billion in dividends, it's clear that there's plenty of ro... |
23,104 | 2022-09-27 00:00:00 UTC | Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-ishares-core-high-dividend-etf-hdv-a-strong-etf-right-now-4 | null | null | The iShares Core High Dividend ETF (HDV) made its debut on 03/29/2011, and is a smart beta exchange traded fund that provides broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
Market cap weighted indexes were created to reflect the market, or a specific segment of the m... | Taking into account individual holdings, Exxon Mobil Corp (XOM) accounts for about 7.15% of the fund's total assets, followed by Johnson & Johnson (JNJ) and Abbvie Inc (ABBV). AbbVie Inc. (ABBV): Free Stock Analysis Report The iShares Core High Dividend ETF (HDV) made its debut on 03/29/2011, and is a smart beta exchan... | Taking into account individual holdings, Exxon Mobil Corp (XOM) accounts for about 7.15% of the fund's total assets, followed by Johnson & Johnson (JNJ) and Abbvie Inc (ABBV). AbbVie Inc. (ABBV): Free Stock Analysis Report Alternatives IShares Core High Dividend ETF is a reasonable option for investors seeking to outpe... | Taking into account individual holdings, Exxon Mobil Corp (XOM) accounts for about 7.15% of the fund's total assets, followed by Johnson & Johnson (JNJ) and Abbvie Inc (ABBV). AbbVie Inc. (ABBV): Free Stock Analysis Report The iShares Core High Dividend ETF (HDV) made its debut on 03/29/2011, and is a smart beta exchan... | Taking into account individual holdings, Exxon Mobil Corp (XOM) accounts for about 7.15% of the fund's total assets, followed by Johnson & Johnson (JNJ) and Abbvie Inc (ABBV). AbbVie Inc. (ABBV): Free Stock Analysis Report The iShares Core High Dividend ETF (HDV) made its debut on 03/29/2011, and is a smart beta exchan... |
23,105 | 2022-09-26 00:00:00 UTC | AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-dips-more-than-broader-markets%3A-what-you-should-know-0 | null | null | AbbVie (ABBV) closed at $141.21 in the latest trading session, marking a -1.29% move from the prior day. This move lagged the S&P 500's daily loss of 1.03%. Meanwhile, the Dow lost 1.11%, and the Nasdaq, a tech-heavy index, lost 0.12%.
Prior to today's trading, shares of the drugmaker had gained 4.92% over the past mon... | AbbVie (ABBV) closed at $141.21 in the latest trading session, marking a -1.29% move from the prior day. ABBV's full-year Zacks Consensus Estimates are calling for earnings of $13.89 per share and revenue of $59.22 billion. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. | AbbVie (ABBV) closed at $141.21 in the latest trading session, marking a -1.29% move from the prior day. ABBV's full-year Zacks Consensus Estimates are calling for earnings of $13.89 per share and revenue of $59.22 billion. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $13.89 per share and revenue of $59.22 billion. AbbVie (ABBV) closed at $141.21 in the latest trading session, marking a -1.29% move from the prior day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. | AbbVie (ABBV) closed at $141.21 in the latest trading session, marking a -1.29% move from the prior day. AbbVie Inc. (ABBV): Free Stock Analysis Report Investors will be hoping for strength from AbbVie as it approaches its next earnings release. |
23,106 | 2022-09-26 00:00:00 UTC | Good Stocks To Buy Right Now? 4 Healthcare Stocks To Know | ABBV | https://www.nasdaq.com/articles/good-stocks-to-buy-right-now-4-healthcare-stocks-to-know | null | null | Healthcare stocks have been on the rise in recent years, as investors have become more interested in the sector. Healthcare stocks are typically seen as defensive investments, as they tend to perform well even during periods of economic uncertainty. Furthermore, the aging population is expected to drive continued growt... | ABBV Recent Stock News Just earlier this month, AbbVie announced its Board of Directors has declared a quarterly cash dividend of $1.41 per share. Healthcare Stocks To Buy [Or Sell] Right Now UnitedHealth Group Inc. (NYSE: UNH) Merck & Company Inc. (NYSE: MRK) AbbVie Inc. (NYSE: ABBV) CVS Health Corporation (NYSE: CVS)... | Healthcare Stocks To Buy [Or Sell] Right Now UnitedHealth Group Inc. (NYSE: UNH) Merck & Company Inc. (NYSE: MRK) AbbVie Inc. (NYSE: ABBV) CVS Health Corporation (NYSE: CVS) 1. AbbVie (ABBV Stock) Following that, AbbVie Inc. (ABBV) is a global, research-based biopharmaceutical company formed in 2013 as a spin-off from ... | Healthcare Stocks To Buy [Or Sell] Right Now UnitedHealth Group Inc. (NYSE: UNH) Merck & Company Inc. (NYSE: MRK) AbbVie Inc. (NYSE: ABBV) CVS Health Corporation (NYSE: CVS) 1. AbbVie (ABBV Stock) Following that, AbbVie Inc. (ABBV) is a global, research-based biopharmaceutical company formed in 2013 as a spin-off from ... | Healthcare Stocks To Buy [Or Sell] Right Now UnitedHealth Group Inc. (NYSE: UNH) Merck & Company Inc. (NYSE: MRK) AbbVie Inc. (NYSE: ABBV) CVS Health Corporation (NYSE: CVS) 1. AbbVie (ABBV Stock) Following that, AbbVie Inc. (ABBV) is a global, research-based biopharmaceutical company formed in 2013 as a spin-off from ... |
23,107 | 2022-09-24 00:00:00 UTC | Is AbbVie a Buy? | ABBV | https://www.nasdaq.com/articles/is-abbvie-a-buy | null | null | Drugmaker AbbVie (NYSE: ABBV) is one of the largest healthcare stocks in the world, with a market cap of over $250 billion. It pays a reasonably high dividend yield and has products in a wide range of therapeutic areas, including eye care, neuroscience, immunology, and oncology. It also owns Botox through its $63 billi... | That leaves plenty of room for it to pursue growth opportunities while still paying (and potentially increasing) its dividend, which AbbVie spent $9.7 billion on in the past year. Drugmaker AbbVie (NYSE: ABBV) is one of the largest healthcare stocks in the world, with a market cap of over $250 billion. AbbVie last repo... | Humira remains key to AbbVie's business for now, generating $5.4 billion this past quarter, nearly three times the $1.8 billion Skyrizi and Rinvoq generated. Drugmaker AbbVie (NYSE: ABBV) is one of the largest healthcare stocks in the world, with a market cap of over $250 billion. AbbVie last reported its earnings in J... | That leaves plenty of room for it to pursue growth opportunities while still paying (and potentially increasing) its dividend, which AbbVie spent $9.7 billion on in the past year. AbbVie's dividend is likely to increase over the years One of the most attractive features about AbbVie's stock is that it offers investors ... | Humira remains key to AbbVie's business for now, generating $5.4 billion this past quarter, nearly three times the $1.8 billion Skyrizi and Rinvoq generated. As a result, AbbVie's valuation hasn't changed significantly, and it's currently trading at 20 times its earnings. Drugmaker AbbVie (NYSE: ABBV) is one of the lar... |
23,108 | 2022-09-23 00:00:00 UTC | Got $1,000? 2 Stocks That Could Be Bargain Buys For 2022 and Beyond | ABBV | https://www.nasdaq.com/articles/got-%241000-2-stocks-that-could-be-bargain-buys-for-2022-and-beyond | null | null | As 2022 draws to a close, it is safe to say Wall Street won't remember this year fondly. Economic problems such as inflation, a persistent pandemic, and geopolitical tensions are some factors contributing to the broader market's poor performance this year. No one can predict when equities will recover, but when they do... | Let's look at two biotech stocks that look attractive at current levels: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD). ABBV data by YCharts. AbbVie AbbVie is one of the largest pharmaceutical companies around. | Let's look at two biotech stocks that look attractive at current levels: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD). ABBV data by YCharts. AbbVie AbbVie is one of the largest pharmaceutical companies around. | Let's look at two biotech stocks that look attractive at current levels: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD). In the second quarter, AbbVie's revenue increased by a decent 4.5% year over year to $14.6 billion. Gilead Sciences Gilead Sciences hasn't performed as well as AbbVie recently. | Let's look at two biotech stocks that look attractive at current levels: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD). ABBV data by YCharts. AbbVie AbbVie is one of the largest pharmaceutical companies around. |
23,109 | 2022-09-23 00:00:00 UTC | Medical device makers see little impact from Fiona on Puerto Rico operations | ABBV | https://www.nasdaq.com/articles/medical-device-makers-see-little-impact-from-fiona-on-puerto-rico-operations | null | null | By Leroy Leo and Khushi Mandowara
Sept 23 (Reuters) - Medical device companies and some drugmakers with manufacturing operations in Puerto Rico said they do not expect meaningful disruption from Hurricane Fiona, which knocked out power for over 3 million people and caused flooding and landslides on the island.
The U.S.... | AbbVie's ABBV.N facilities are intact and operational and unlikely to see any patient impact or product shortages due to Fiona, according to a person familiar with the company's operations who asked not to be named. By Leroy Leo and Khushi Mandowara Sept 23 (Reuters) - Medical device companies and some drugmakers with ... | AbbVie's ABBV.N facilities are intact and operational and unlikely to see any patient impact or product shortages due to Fiona, according to a person familiar with the company's operations who asked not to be named. By Leroy Leo and Khushi Mandowara Sept 23 (Reuters) - Medical device companies and some drugmakers with ... | AbbVie's ABBV.N facilities are intact and operational and unlikely to see any patient impact or product shortages due to Fiona, according to a person familiar with the company's operations who asked not to be named. By Leroy Leo and Khushi Mandowara Sept 23 (Reuters) - Medical device companies and some drugmakers with ... | AbbVie's ABBV.N facilities are intact and operational and unlikely to see any patient impact or product shortages due to Fiona, according to a person familiar with the company's operations who asked not to be named. By Leroy Leo and Khushi Mandowara Sept 23 (Reuters) - Medical device companies and some drugmakers with ... |
23,110 | 2022-09-23 00:00:00 UTC | Use These 3 Simple Tricks to Maximize Your Returns From AbbVie Stock | ABBV | https://www.nasdaq.com/articles/use-these-3-simple-tricks-to-maximize-your-returns-from-abbvie-stock | null | null | As one of the world's largest pharmaceutical companies, it's no surprise to hear that AbbVie (NYSE: ABBV) has plenty of moving parts for investors to think about when they're wondering what to do to make the most money from their shares. If you don't understand the factors that make the stock go up and how to make the ... | As one of the world's largest pharmaceutical companies, it's no surprise to hear that AbbVie (NYSE: ABBV) has plenty of moving parts for investors to think about when they're wondering what to do to make the most money from their shares. And that's why you need to know three simple tricks to flourish as an AbbVie share... | In contrast, buying shares right after AbbVie reports bad clinical trial results and its stock is dented might be a good idea, as it's likely that another set of results will eventually come along and erase the damage. Over the last 12 months, AbbVie spent more than $1.6 billion of its free cash flow (FCF) of around $2... | Over the last 12 months, AbbVie spent more than $1.6 billion of its free cash flow (FCF) of around $22.2 billion to buy back its shares, thereby reducing the number of shares outstanding and pumping up their value for shareholders. As one of the world's largest pharmaceutical companies, it's no surprise to hear that Ab... | As one of the world's largest pharmaceutical companies, it's no surprise to hear that AbbVie (NYSE: ABBV) has plenty of moving parts for investors to think about when they're wondering what to do to make the most money from their shares. And that's why you need to know three simple tricks to flourish as an AbbVie share... |
23,111 | 2022-09-23 00:00:00 UTC | What Could This Drug News Mean for AbbVie? | ABBV | https://www.nasdaq.com/articles/what-could-this-drug-news-mean-for-abbvie | null | null | In late July, AbbVie (NYSE: ABBV) applied for a new indication with the European Medicines Agency (EMA) for Rinvoq to treat adult patients with moderate-to-severe Crohn's disease.
Thanks to encouraging phase 3 clinical trial results, the indication will likely be approved within the next several months. But how much co... | In late July, AbbVie (NYSE: ABBV) applied for a new indication with the European Medicines Agency (EMA) for Rinvoq to treat adult patients with moderate-to-severe Crohn's disease. This would be a $400 million lift to AbbVie's annual sales, which may not seem like much stacked against the $59 billion in revenue that ana... | In late July, AbbVie (NYSE: ABBV) applied for a new indication with the European Medicines Agency (EMA) for Rinvoq to treat adult patients with moderate-to-severe Crohn's disease. This would be a $400 million lift to AbbVie's annual sales, which may not seem like much stacked against the $59 billion in revenue that ana... | In late July, AbbVie (NYSE: ABBV) applied for a new indication with the European Medicines Agency (EMA) for Rinvoq to treat adult patients with moderate-to-severe Crohn's disease. However, adding in the potential Crohn's disease indication in the U.S. and other markets, Rinvoq could generate well over $1 billion in ann... | However, adding in the potential Crohn's disease indication in the U.S. and other markets, Rinvoq could generate well over $1 billion in annual revenue for AbbVie from Crohn's disease alone. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! I... |
23,112 | 2022-09-22 00:00:00 UTC | Interesting ABBV Put And Call Options For November 4th | ABBV | https://www.nasdaq.com/articles/interesting-abbv-put-and-call-options-for-november-4th | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the November 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new November 4th contracts and identified one put and one call contract of particular interest.
The put c... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $145.00 strike highlighted in red: Considering the fact that the $145.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $135.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $145.00 strike price has a current bid of $3.55. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new November 4th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $145.00 strike highlighted in red: Consid... |
23,113 | 2022-09-22 00:00:00 UTC | 3 Dividend Stocks You Can Safely Hold for Decades | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-you-can-safely-hold-for-decades-4 | null | null | A good dividend stock is one you won't want to let go of. Why? Because dividend stocks offer you annual passive income. And of course, by choosing a company with solid earnings growth over time, you're likely to benefit from share price performance over time, too.
One good way to start your search is by looking at Divi... | AbbVie's earnings and dividend track record and prospects for newer immunology drugs are great reasons to be confident about this company -- and to hang onto the stock for the long haul. AbbVie AbbVie (NYSE: ABBV) sells the biggest blockbuster of all time. AbbVie's two other immunology drugs -- Skyrizi and Rinvoq -- to... | ABBV Net Income (Annual) data by YCharts Now let's take a look at the annual dividend. AbbVie AbbVie (NYSE: ABBV) sells the biggest blockbuster of all time. AbbVie's two other immunology drugs -- Skyrizi and Rinvoq -- together are set to eventually surpass peak sales of Humira. | AbbVie's earnings and dividend track record and prospects for newer immunology drugs are great reasons to be confident about this company -- and to hang onto the stock for the long haul. AbbVie AbbVie (NYSE: ABBV) sells the biggest blockbuster of all time. AbbVie's two other immunology drugs -- Skyrizi and Rinvoq -- to... | AbbVie AbbVie (NYSE: ABBV) sells the biggest blockbuster of all time. AbbVie's two other immunology drugs -- Skyrizi and Rinvoq -- together are set to eventually surpass peak sales of Humira. In the second quarter, AbbVie said global Skyrizi and Rinvoq revenues soared more than 85% and 56%, respectively. |
23,114 | 2022-09-21 00:00:00 UTC | Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? | ABBV | https://www.nasdaq.com/articles/is-trending-stock-abbvie-inc.-abbv-a-buy-now-1 | null | null | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this drugmaker have returned +2%, compared to the Zacks S&P 500 composite's -8.7% change. During this ... | Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. During this period, the Zacks Large Cap Pharmaceuticals indus... | Last Reported Results and Surprise History AbbVie reported revenues of $14.58 billion in the last reported quarter, representing a year-over-year change of +4.5%. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVi... | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has lost 5.6%. For the current quarter, AbbVie is expected to post earnings of $3.59 per share, indicating a change of +7.8% from the year-ago quarter. | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has lost 5.6%. For the current quarter, AbbVie is expected to post earnings of $3.59 per share, indicating a change of +7.8% from the year-ago quarter. |
23,115 | 2022-09-20 00:00:00 UTC | The Zacks Analyst Blog Highlights Apple, Amazon, AbbVie, Philip Morris International and BlackRock | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-apple-amazon-abbvie-philip-morris-international-and | null | null | For Immediate Release
Chicago, IL – September 20, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Apple Inc. AAPL, Amazon.... | Stocks recently featured in the blog include: Apple Inc. AAPL, Amazon.com, Inc. AMZN, AbbVie Inc. ABBV, Philip Morris International Inc. PM and BlackRock, Inc. BLK. Here are highlights from Monday’s Analyst Blog: Top Analyst Reports for Apple, Amazon and AbbVie The Zacks Research Daily presents the best research output... | Stocks recently featured in the blog include: Apple Inc. AAPL, Amazon.com, Inc. AMZN, AbbVie Inc. ABBV, Philip Morris International Inc. PM and BlackRock, Inc. BLK. Here are highlights from Monday’s Analyst Blog: Top Analyst Reports for Apple, Amazon and AbbVie The Zacks Research Daily presents the best research output... | Here are highlights from Monday’s Analyst Blog: Top Analyst Reports for Apple, Amazon and AbbVie The Zacks Research Daily presents the best research output of our analyst team. Increasing competition from newer therapies is hurting Imbruvica’s sales (You can read the full research report on AbbVie here >>>) Other notew... | Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., Amazon.com, Inc. and AbbVie Inc. Stocks recently featured in the blog include: Apple Inc. AAPL, Amazon.com, Inc. AMZN, AbbVie Inc. ABBV, Philip Morris International Inc. PM and BlackRock, Inc. BLK. Here are highlights from Mo... |
23,116 | 2022-09-20 00:00:00 UTC | AbbVie (ABBV) Gets CHMP Nod for Skyrizi in a Third Indication | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gets-chmp-nod-for-skyrizi-in-a-third-indication | null | null | AbbVie ABBV announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its interleukin-23 (“IL-23”) inhibitor, Skyrizi (risankizumab) to treat moderate-to-severe Crohn’s disease (“CD”).
A final decision by the European Commission (EC) is expected i... | AbbVie ABBV announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its interleukin-23 (“IL-23”) inhibitor, Skyrizi (risankizumab) to treat moderate-to-severe Crohn’s disease (“CD”). In the year so far, shares of AbbVie have declined 5.4% agains... | AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Zacks Rank & Stock to Consider AbbVie currently carries a Zacks Rank #3 (Hold). AbbVie ABBV announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its interleukin-23 (“IL-23”) inhibitor, S... | AbbVie ABBV announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its interleukin-23 (“IL-23”) inhibitor, Skyrizi (risankizumab) to treat moderate-to-severe Crohn’s disease (“CD”). AbbVie is developing Skyrizi in collaboration with Boehringer ... | AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Zacks Rank & Stock to Consider AbbVie currently carries a Zacks Rank #3 (Hold). AbbVie ABBV announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its interleukin-23 (“IL-23”) inhibitor, S... |
23,117 | 2022-09-20 00:00:00 UTC | 2 Dividend Stocks to Double Up On Right Now | ABBV | https://www.nasdaq.com/articles/2-dividend-stocks-to-double-up-on-right-now-0 | null | null | AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) have much in common. They are huge pharmaceutical companies that have a long record of success, consistent revenue growth, and regular dividends, and yet they are underpriced.
AbbVie's shares have been sluggish for the past couple of years because of concerns about th... | AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) have much in common. AbbVie's shares have been sluggish for the past couple of years because of concerns about the pending patent cliff in the U.S. for its blockbuster immunology drug Humira, while GlaxoSmithKline's shares have suffered recently because of concerns ab... | AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) have much in common. AbbVie's shares have been sluggish for the past couple of years because of concerns about the pending patent cliff in the U.S. for its blockbuster immunology drug Humira, while GlaxoSmithKline's shares have suffered recently because of concerns ab... | AbbVie's shares have been sluggish for the past couple of years because of concerns about the pending patent cliff in the U.S. for its blockbuster immunology drug Humira, while GlaxoSmithKline's shares have suffered recently because of concerns about lawsuits regarding its recalled indigestion drug, Zantac. See the 10 ... | AbbVie's shares have been sluggish for the past couple of years because of concerns about the pending patent cliff in the U.S. for its blockbuster immunology drug Humira, while GlaxoSmithKline's shares have suffered recently because of concerns about lawsuits regarding its recalled indigestion drug, Zantac. AbbVie (NYS... |
23,118 | 2022-09-19 00:00:00 UTC | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-sinks-as-market-gains%3A-what-you-should-know-4 | null | null | AbbVie (ABBV) closed the most recent trading day at $142.66, moving -0.97% from the previous trading session. This move lagged the S&P 500's daily gain of 0.69%. Meanwhile, the Dow gained 0.64%, and the Nasdaq, a tech-heavy index, lost 0.2%.
Prior to today's trading, shares of the drugmaker had gained 1.56% over the pa... | AbbVie (ABBV) closed the most recent trading day at $142.66, moving -0.97% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. Investors might also notice recent changes to analyst estimates for AbbVie. | AbbVie (ABBV) closed the most recent trading day at $142.66, moving -0.97% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. Investors might also notice recent changes to analyst estimates for AbbVie. | AbbVie (ABBV) closed the most recent trading day at $142.66, moving -0.97% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. Investors might also notice recent changes to analyst estimates for AbbVie. | AbbVie (ABBV) closed the most recent trading day at $142.66, moving -0.97% from the previous trading session. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. Investors might also notice recent changes to analyst estimates for AbbVie. |
23,119 | 2022-09-19 00:00:00 UTC | Top Analyst Reports for Apple, Amazon.com & AbbVie | ABBV | https://www.nasdaq.com/articles/top-analyst-reports-for-apple-amazon.com-abbvie | null | null | Monday, September 19, 2022
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Amazon.com, Inc. (AMZN) and AbbVie Inc. (ABBV). These research reports have been hand-picked from the roughly... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Robust Portfolio, Services Strength to Benefit Apple (AAPL) Amazon (AMZN) Rides on Prime Strength & Growing AWS Adoption AbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth Featured Reports Cancer Drug... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Robust Portfolio, Services Strength to Benefit Apple (AAPL) Amazon (AMZN) Rides on Prime Strength & Growing AWS Adoption AbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth Featured Reports Cancer Drug... | Increasing competition from newer therapies is hurting Imbruvica’s sales (You can read the full research report on AbbVie here >>>) Other noteworthy reports we are featuring today include AstraZeneca PLC (AZN), Philip Morris International Inc. (PM), and BlackRock, Inc. (BLK). If you want an email notification each time... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Robust Portfolio, Services Strength to Benefit Apple (AAPL) Amazon (AMZN) Rides on Prime Strength & Growing AWS Adoption AbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth Featured Reports Cancer Drug... |
23,120 | 2022-09-19 00:00:00 UTC | VOO, JNJ, LLY, ABBV: Large Inflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/voo-jnj-lly-abbv%3A-large-inflows-detected-at-etf | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard S&P 500 ETF (Symbol: VOO) where we have detected an approximate $3.4 billion dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 716,557,429 to 725,989... | Among the largest underlying components of VOO, in trading today Johnson & Johnson (Symbol: JNJ) is off about 1.5%, Eli Lilly (Symbol: LLY) is down about 3.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.1%. For a complete list of holdings, visit the VOO Holdings page » The chart below shows the one year price pe... | Among the largest underlying components of VOO, in trading today Johnson & Johnson (Symbol: JNJ) is off about 1.5%, Eli Lilly (Symbol: LLY) is down about 3.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.1%. For a complete list of holdings, visit the VOO Holdings page » The chart below shows the one year price pe... | Among the largest underlying components of VOO, in trading today Johnson & Johnson (Symbol: JNJ) is off about 1.5%, Eli Lilly (Symbol: LLY) is down about 3.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chann... | Among the largest underlying components of VOO, in trading today Johnson & Johnson (Symbol: JNJ) is off about 1.5%, Eli Lilly (Symbol: LLY) is down about 3.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chann... |
23,121 | 2022-09-19 00:00:00 UTC | How To Start Investing In Stocks Today | ABBV | https://www.nasdaq.com/articles/how-to-start-investing-in-stocks-today | null | null | Investing in the stock market can be a great way to make money and build your wealth. While there is always some risk involved, if you know what you’re doing, you can minimize your risk and maximize your chances of making a profit. One of the biggest benefits of investing in the stock market is that it gives you the op... | Some of the more popular dividend-paying stocks in the stock market now are names like AbbVie Inc. (NYSE: ABBV), and UnitedHealth Group Inc. (NYSE: UNH). One of the biggest benefits of investing in the stock market is that it gives you the opportunity to buy shares of companies that are doing well and that have a lot o... | Some of the more popular dividend-paying stocks in the stock market now are names like AbbVie Inc. (NYSE: ABBV), and UnitedHealth Group Inc. (NYSE: UNH). How To Start Investing In Stocks Determine Your Investing Goals Choose Your Risk Tolerance Decide On Your Investment Strategy Choose An Investment Account Create A Bu... | Some of the more popular dividend-paying stocks in the stock market now are names like AbbVie Inc. (NYSE: ABBV), and UnitedHealth Group Inc. (NYSE: UNH). How To Start Investing In Stocks Determine Your Investing Goals Choose Your Risk Tolerance Decide On Your Investment Strategy Choose An Investment Account Create A Bu... | Some of the more popular dividend-paying stocks in the stock market now are names like AbbVie Inc. (NYSE: ABBV), and UnitedHealth Group Inc. (NYSE: UNH). Investing in the stock market can be a great way to make money and build your wealth. How To Start Investing In Stocks Determine Your Investing Goals Choose Your Risk... |
23,122 | 2022-09-19 00:00:00 UTC | The Zacks Analyst Blog Highlights AbbVie, Novartis, Merck and AstraZeneca | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-abbvie-novartis-merck-and-astrazeneca | null | null | For Immediate Release
Chicago, IL – September 19, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie ABBV, Novartis NV... | Stocks recently featured in the blog include: AbbVie ABBV, Novartis NVS, Merck MRK and AstraZeneca AZN. Among the large drugmakers, AbbVie, Novartis, Merck and AstraZeneca are worth retaining in your portfolio. 4 Large Drugmakers to Keep an Eye On AbbVie: AbbVie has successfully expanded the labels of its cancer drugs,... | Stocks recently featured in the blog include: AbbVie ABBV, Novartis NVS, Merck MRK and AstraZeneca AZN. Among the large drugmakers, AbbVie, Novartis, Merck and AstraZeneca are worth retaining in your portfolio. 4 Large Drugmakers to Keep an Eye On AbbVie: AbbVie has successfully expanded the labels of its cancer drugs,... | Stocks recently featured in the blog include: AbbVie ABBV, Novartis NVS, Merck MRK and AstraZeneca AZN. Among the large drugmakers, AbbVie, Novartis, Merck and AstraZeneca are worth retaining in your portfolio. 4 Large Drugmakers to Keep an Eye On AbbVie: AbbVie has successfully expanded the labels of its cancer drugs,... | Stocks recently featured in the blog include: AbbVie ABBV, Novartis NVS, Merck MRK and AstraZeneca AZN. Among the large drugmakers, AbbVie, Novartis, Merck and AstraZeneca are worth retaining in your portfolio. 4 Large Drugmakers to Keep an Eye On AbbVie: AbbVie has successfully expanded the labels of its cancer drugs,... |
23,123 | 2022-09-19 00:00:00 UTC | 4 Strategies to Try if You Need Extra Cash From Your Investments | ABBV | https://www.nasdaq.com/articles/4-strategies-to-try-if-you-need-extra-cash-from-your-investments | null | null | When it comes to successful long-term investing, it's a good idea to focus on total return: the combination of price appreciation and dividend payments. However, there are times when you might think about optimizing for cash flow instead. If you have upcoming obligations that can't be covered by your job income alone -... | Here, I refer to companies like AT&T, AbbVie, and Kinder Morgan -- among other value stocks. When it comes to successful long-term investing, it's a good idea to focus on total return: the combination of price appreciation and dividend payments. If you have upcoming obligations that can't be covered by your job income ... | Here, I refer to companies like AT&T, AbbVie, and Kinder Morgan -- among other value stocks. Set dividends to cash If you own stocks that pay dividends, be sure to have the account setting turned on that allows for dividends to appear as cash in your account. To squeeze a little more cash out of your investments, focus... | Here, I refer to companies like AT&T, AbbVie, and Kinder Morgan -- among other value stocks. Focus on dividend payers Many stocks across the investment universe are known for their ability to generate cash, and in many cases even to increase their dividend. Set dividends to cash If you own stocks that pay dividends, be... | Here, I refer to companies like AT&T, AbbVie, and Kinder Morgan -- among other value stocks. Set dividends to cash If you own stocks that pay dividends, be sure to have the account setting turned on that allows for dividends to appear as cash in your account. Pause for a moment Before investing too much money in the st... |
23,124 | 2022-09-19 00:00:00 UTC | AbbVie Receives CHMP Positive Opinion For Skyrizi For Moderate To Severe Crohn's Disease | ABBV | https://www.nasdaq.com/articles/abbvie-receives-chmp-positive-opinion-for-skyrizi-for-moderate-to-severe-crohns-disease | null | null | (RTTNews) - AbbVie Inc. (ABBV) said on Monday that the Committee for Medicinal Products for Human Use has adopted positive opinion to extend the indication of Skyrizi for the treatment of adults with moderate to severe Crohn's Disease in the European Union.
The European Commission's final decision on the drug is antici... | (RTTNews) - AbbVie Inc. (ABBV) said on Monday that the Committee for Medicinal Products for Human Use has adopted positive opinion to extend the indication of Skyrizi for the treatment of adults with moderate to severe Crohn's Disease in the European Union. Skyrizi has been developed as part of a collaboration between ... | (RTTNews) - AbbVie Inc. (ABBV) said on Monday that the Committee for Medicinal Products for Human Use has adopted positive opinion to extend the indication of Skyrizi for the treatment of adults with moderate to severe Crohn's Disease in the European Union. Skyrizi has been developed as part of a collaboration between ... | (RTTNews) - AbbVie Inc. (ABBV) said on Monday that the Committee for Medicinal Products for Human Use has adopted positive opinion to extend the indication of Skyrizi for the treatment of adults with moderate to severe Crohn's Disease in the European Union. Skyrizi has been developed as part of a collaboration between ... | (RTTNews) - AbbVie Inc. (ABBV) said on Monday that the Committee for Medicinal Products for Human Use has adopted positive opinion to extend the indication of Skyrizi for the treatment of adults with moderate to severe Crohn's Disease in the European Union. Skyrizi has been developed as part of a collaboration between ... |
23,125 | 2022-09-16 00:00:00 UTC | Bristol Myers, AbbVie plan to cut up to 360 California jobs | ABBV | https://www.nasdaq.com/articles/bristol-myers-abbvie-plan-to-cut-up-to-360-california-jobs | null | null | Sept 16 (Reuters) - Drugmakers Bristol Myers Squibb Co BMY.N and AbbVie Inc ABBV.O told California officials that they plan to cut up to 360 jobs there in unrelated moves, according to notices filed with the state that were made public earlier this week.
Bristol Myers plans to cut up to 261 jobs in two different locati... | Sept 16 (Reuters) - Drugmakers Bristol Myers Squibb Co BMY.N and AbbVie Inc ABBV.O told California officials that they plan to cut up to 360 jobs there in unrelated moves, according to notices filed with the state that were made public earlier this week. Separately, AbbVie plans to cut up to 99 jobs in Irvine, Calif., ... | Separately, AbbVie plans to cut up to 99 jobs in Irvine, Calif., the company told the state. Sept 16 (Reuters) - Drugmakers Bristol Myers Squibb Co BMY.N and AbbVie Inc ABBV.O told California officials that they plan to cut up to 360 jobs there in unrelated moves, according to notices filed with the state that were mad... | Sept 16 (Reuters) - Drugmakers Bristol Myers Squibb Co BMY.N and AbbVie Inc ABBV.O told California officials that they plan to cut up to 360 jobs there in unrelated moves, according to notices filed with the state that were made public earlier this week. Separately, AbbVie plans to cut up to 99 jobs in Irvine, Calif., ... | Sept 16 (Reuters) - Drugmakers Bristol Myers Squibb Co BMY.N and AbbVie Inc ABBV.O told California officials that they plan to cut up to 360 jobs there in unrelated moves, according to notices filed with the state that were made public earlier this week. Separately, AbbVie plans to cut up to 99 jobs in Irvine, Calif., ... |
23,126 | 2022-09-16 00:00:00 UTC | 4 Large Drug Stocks to Watch as Fundamentals Stay Strong | ABBV | https://www.nasdaq.com/articles/4-large-drug-stocks-to-watch-as-fundamentals-stay-strong | null | null | Investors flocked to the biotech industry during the pandemic years of 2020 and 2021. The successful vaccines and effective antivirals made by the big drugmakers sent the pandemic to the rear-view mirror early his year. However, the post-pandemic trade recovery and strong economic growth have shifted investors’ money t... | Among the large drugmakers, AbbVie ABBV, Novartis NVS, Merck MRK and AstraZeneca AZN are worth retaining in your portfolio. Forward 12-Month Price-to-Earnings (P/E) Ratio 4 Large Drugmakers to Keep an Eye On AbbVie: AbbVie has successfully expanded the labels of its cancer drugs, Imbruvica and Venclexta. AbbVie has sev... | Among the large drugmakers, AbbVie ABBV, Novartis NVS, Merck MRK and AstraZeneca AZN are worth retaining in your portfolio. Forward 12-Month Price-to-Earnings (P/E) Ratio 4 Large Drugmakers to Keep an Eye On AbbVie: AbbVie has successfully expanded the labels of its cancer drugs, Imbruvica and Venclexta. AbbVie has sev... | Among the large drugmakers, AbbVie ABBV, Novartis NVS, Merck MRK and AstraZeneca AZN are worth retaining in your portfolio. Forward 12-Month Price-to-Earnings (P/E) Ratio 4 Large Drugmakers to Keep an Eye On AbbVie: AbbVie has successfully expanded the labels of its cancer drugs, Imbruvica and Venclexta. AbbVie has sev... | Price and Consensus: ABBV Merck: Merck has a Zacks Rank of 3. Among the large drugmakers, AbbVie ABBV, Novartis NVS, Merck MRK and AstraZeneca AZN are worth retaining in your portfolio. Forward 12-Month Price-to-Earnings (P/E) Ratio 4 Large Drugmakers to Keep an Eye On AbbVie: AbbVie has successfully expanded the label... |
23,127 | 2022-09-16 00:00:00 UTC | We Ran A Stock Scan For Earnings Growth And AbbVie (NYSE:ABBV) Passed With Ease | ABBV | https://www.nasdaq.com/articles/we-ran-a-stock-scan-for-earnings-growth-and-abbvie-nyse%3Aabbv-passed-with-ease | null | null | Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' Loss-making companies are always racing against time to reach financial sustain... | Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like AbbVie (NYSE:ABBV). NYSE:ABBV Earnings and Revenue History September 16th 2022 While we live in the present moment, there's little doubt that the future matters m... | Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like AbbVie (NYSE:ABBV). How Fast Is AbbVie Growing? AbbVie's shareholders have have plenty to be happy about as their annual EPS growth for the last 3 years was 37%. | Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like AbbVie (NYSE:ABBV). How Fast Is AbbVie Growing? AbbVie's shareholders have have plenty to be happy about as their annual EPS growth for the last 3 years was 37%. | AbbVie's shareholders have have plenty to be happy about as their annual EPS growth for the last 3 years was 37%. So based on this quick analysis, we do think it's worth considering AbbVie for a spot on your watchlist. Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditio... |
23,128 | 2022-09-15 00:00:00 UTC | Noteworthy Thursday Option Activity: ABBV, LAZ, GOGO | ABBV | https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-abbv-laz-gogo | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 21,587 contracts has been traded thus far today, a contract volume which is representative of approximately 2.2 million underlying shares (given that e... | Especially high volume was seen for the $142 strike call option expiring September 16, 2022, with 2,384 contracts trading so far today, representing approximately 238,400 underlying shares of ABBV. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AbbV... | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 21,587 contracts has been traded thus far today, a contract volume which is representative of approximately 2.2 million underlying shares (given that e... | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 21,587 contracts has been traded thus far today, a contract volume which is representative of approximately 2.2 million underlying shares (given that e... | Below is a chart showing ABBV's trailing twelve month trading history, with the $142 strike highlighted in orange: Lazard (Symbol: LAZ) saw options trading volume of 3,082 contracts, representing approximately 308,200 underlying shares or approximately 49.6% of LAZ's average daily trading volume over the past month, of... |
23,129 | 2022-09-15 00:00:00 UTC | 7 Top-Rated Biotech Stocks to Buy for Q4 | ABBV | https://www.nasdaq.com/articles/7-top-rated-biotech-stocks-to-buy-for-q4 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter.
The new National Biotechnology and Biomanufacturing Initiative is designed to encourage bi... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) is one of the best-known biotech stocks in the U.S., after having spun off from Abbott Laboratories (NYSE:ABT). Analysts are expecting AbbVie’s Skyrizi and Rinvoq drugs to replace Humira’s revenue, as the two drugs are collectively expected to gener... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) is one of the best-known biotech stocks in the U.S., after having spun off from Abbott Laboratories (NYSE:ABT). Analysts are expecting AbbVie’s Skyrizi and Rinvoq drugs to replace Humira’s revenue, as the two drugs are collectively expected to gener... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) is one of the best-known biotech stocks in the U.S., after having spun off from Abbott Laboratories (NYSE:ABT). Analysts are expecting AbbVie’s Skyrizi and Rinvoq drugs to replace Humira’s revenue, as the two drugs are collectively expected to gener... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) is one of the best-known biotech stocks in the U.S., after having spun off from Abbott Laboratories (NYSE:ABT). Analysts are expecting AbbVie’s Skyrizi and Rinvoq drugs to replace Humira’s revenue, as the two drugs are collectively expected to gener... |
23,130 | 2022-09-13 00:00:00 UTC | 3 Unstoppable Dividend Stocks to Buy in September | ABBV | https://www.nasdaq.com/articles/3-unstoppable-dividend-stocks-to-buy-in-september | null | null | When it comes to finding a great dividend stock to add to your investment portfolio, there's a wide variety of stocks to choose from. Some, for instance, have stronger underlying businesses than others.
We asked three Motley Fool contributors to pick unstoppable dividend stocks to buy in September. They chose Abbott La... | AbbVie: More revenue-generating drugs in the pipeline Keith Speights: This September pick shares a lot in common with Abbott Labs. They chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Gilead Sciences (NASDAQ: GILD). Prior to 2013, AbbVie was part of Abbott. | They chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Gilead Sciences (NASDAQ: GILD). AbbVie: More revenue-generating drugs in the pipeline Keith Speights: This September pick shares a lot in common with Abbott Labs. Prior to 2013, AbbVie was part of Abbott. | They chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Gilead Sciences (NASDAQ: GILD). AbbVie: More revenue-generating drugs in the pipeline Keith Speights: This September pick shares a lot in common with Abbott Labs. Prior to 2013, AbbVie was part of Abbott. | They chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Gilead Sciences (NASDAQ: GILD). AbbVie: More revenue-generating drugs in the pipeline Keith Speights: This September pick shares a lot in common with Abbott Labs. Prior to 2013, AbbVie was part of Abbott. |
23,131 | 2022-09-13 00:00:00 UTC | 3 No-Brainer Stocks to Buy in a Correction | ABBV | https://www.nasdaq.com/articles/3-no-brainer-stocks-to-buy-in-a-correction-1 | null | null | "Buy your straw hats in the winter." This adage is a terrific way to illustrate that buying quality stocks when demand is low will pay off when demand is up. As Warren Buffet once said, "Whether we're talking about socks or stocks, I like buying quality merchandise when it is marked down."
Weaker demand for stocks usua... | Grab AbbVie's enticing yield Solid dividend stocks can be like a feathery pillow helping you to sleep well every night. "Best-in-breed" companies that have massive moats and pay impressive yields are a great place to start, and Amazon (NASDAQ: AMZN), Intuitive Surgical (NASDAQ: ISRG), and AbbVie (NYSE: ABBV) are three ... | "Best-in-breed" companies that have massive moats and pay impressive yields are a great place to start, and Amazon (NASDAQ: AMZN), Intuitive Surgical (NASDAQ: ISRG), and AbbVie (NYSE: ABBV) are three fantastic examples. Grab AbbVie's enticing yield Solid dividend stocks can be like a feathery pillow helping you to slee... | "Best-in-breed" companies that have massive moats and pay impressive yields are a great place to start, and Amazon (NASDAQ: AMZN), Intuitive Surgical (NASDAQ: ISRG), and AbbVie (NYSE: ABBV) are three fantastic examples. Grab AbbVie's enticing yield Solid dividend stocks can be like a feathery pillow helping you to slee... | "Best-in-breed" companies that have massive moats and pay impressive yields are a great place to start, and Amazon (NASDAQ: AMZN), Intuitive Surgical (NASDAQ: ISRG), and AbbVie (NYSE: ABBV) are three fantastic examples. Grab AbbVie's enticing yield Solid dividend stocks can be like a feathery pillow helping you to slee... |
23,132 | 2022-09-13 00:00:00 UTC | Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar? | ABBV | https://www.nasdaq.com/articles/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar-2 | null | null | Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the First Trust Morningstar Dividend Leaders ETF (FDL) is a passively managed exchange traded fund launched on 03/09/2006.
The fund is sponsored by First Trust Advisors. It has amassed assets over $3.41 billion, making it one of ... | Looking at individual holdings, Exxon Mobil Corporation (XOM) accounts for about 8.91% of total assets, followed by Verizon Communications Inc. (VZ) and Abbvie Inc. (ABBV). AbbVie Inc. (ABBV): Free Stock Analysis Report Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the First... | Looking at individual holdings, Exxon Mobil Corporation (XOM) accounts for about 8.91% of total assets, followed by Verizon Communications Inc. (VZ) and Abbvie Inc. (ABBV). AbbVie Inc. (ABBV): Free Stock Analysis Report Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the First... | Looking at individual holdings, Exxon Mobil Corporation (XOM) accounts for about 8.91% of total assets, followed by Verizon Communications Inc. (VZ) and Abbvie Inc. (ABBV). AbbVie Inc. (ABBV): Free Stock Analysis Report Alternatives First Trust Morningstar Dividend Leaders ETF holds a Zacks ETF Rank of 2 (Buy), which i... | Looking at individual holdings, Exxon Mobil Corporation (XOM) accounts for about 8.91% of total assets, followed by Verizon Communications Inc. (VZ) and Abbvie Inc. (ABBV). AbbVie Inc. (ABBV): Free Stock Analysis Report Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the First... |
23,133 | 2022-09-12 00:00:00 UTC | AbbVie (ABBV) Gains But Lags Market: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gains-but-lags-market%3A-what-you-should-know-5 | null | null | AbbVie (ABBV) closed at $142.24 in the latest trading session, marking a +0.58% move from the prior day. This change lagged the S&P 500's 1.06% gain on the day. Elsewhere, the Dow gained 0.71%, while the tech-heavy Nasdaq added 0.09%.
Heading into today, shares of the drugmaker had lost 0.83% over the past month, outpa... | AbbVie (ABBV) closed at $142.24 in the latest trading session, marking a +0.58% move from the prior day. ABBV's full-year Zacks Consensus Estimates are calling for earnings of $13.90 per share and revenue of $59.23 billion. AbbVie will be looking to display strength as it nears its next earnings release. | On that day, AbbVie is projected to report earnings of $3.59 per share, which would represent year-over-year growth of 7.81%. AbbVie (ABBV) closed at $142.24 in the latest trading session, marking a +0.58% move from the prior day. AbbVie will be looking to display strength as it nears its next earnings release. | AbbVie (ABBV) closed at $142.24 in the latest trading session, marking a +0.58% move from the prior day. AbbVie will be looking to display strength as it nears its next earnings release. On that day, AbbVie is projected to report earnings of $3.59 per share, which would represent year-over-year growth of 7.81%. | On that day, AbbVie is projected to report earnings of $3.59 per share, which would represent year-over-year growth of 7.81%. AbbVie currently has a Zacks Rank of #3 (Hold). AbbVie (ABBV) closed at $142.24 in the latest trading session, marking a +0.58% move from the prior day. |
23,134 | 2022-09-12 00:00:00 UTC | AbbVie a Top Ranked SAFE Dividend Stock With 4.0% Yield (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-a-top-ranked-safe-dividend-stock-with-4.0-yield-abbv | null | null | AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.0% yield, as well as a superb track record of at least two decades of dividend growth, according to the most recent ''DividendRank'' report.
Accor... | Below is a long-term dividend history chart for ABBV, which the report stressed as being of key importance. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying h... | AbbVie Inc (Symbol: ABBV) made the "Dividend Channel S.A.F.E. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying holding representing 1.21% of the SPDR S&P Divi... | According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying holding representing 1.21% of the SPDR S&P Dividend ETF (SDY), which holds $269,869,124 worth of ABBV shares. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E.... | AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel, AbbVie Inc is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying holding representing 1.21% of the SPDR S&P Dividend ETF (SDY), which holds $269,869,124 worth of ABBV shares.... |
23,135 | 2022-09-12 00:00:00 UTC | Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)? | ABBV | https://www.nasdaq.com/articles/should-you-invest-in-the-invesco-dynamic-pharmaceuticals-etf-pjp-3 | null | null | Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the Invesco Dynamic Pharmaceuticals ETF (PJP), a passively managed exchange traded fund launched on 06/23/2005.
Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors ... | Looking at individual holdings, Eli Lilly & Co (LLY) accounts for about 5.80% of total assets, followed by Abbvie Inc (ABBV) and Johnson & Johnson (JNJ). AbbVie Inc. (ABBV): Free Stock Analysis Report Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their lo... | Looking at individual holdings, Eli Lilly & Co (LLY) accounts for about 5.80% of total assets, followed by Abbvie Inc (ABBV) and Johnson & Johnson (JNJ). AbbVie Inc. (ABBV): Free Stock Analysis Report You should consider the Invesco Dynamic Pharmaceuticals ETF (PJP), a passively managed exchange traded fund launched on... | Looking at individual holdings, Eli Lilly & Co (LLY) accounts for about 5.80% of total assets, followed by Abbvie Inc (ABBV) and Johnson & Johnson (JNJ). AbbVie Inc. (ABBV): Free Stock Analysis Report Alternatives Invesco Dynamic Pharmaceuticals ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset... | Looking at individual holdings, Eli Lilly & Co (LLY) accounts for about 5.80% of total assets, followed by Abbvie Inc (ABBV) and Johnson & Johnson (JNJ). AbbVie Inc. (ABBV): Free Stock Analysis Report Investors might also want to consider some other ETF options in the space. |
23,136 | 2022-09-11 00:00:00 UTC | Best Stocks To Buy Now? 4 Biotech Stocks In Focus | ABBV | https://www.nasdaq.com/articles/best-stocks-to-buy-now-4-biotech-stocks-in-focus | null | null | 4 Biotech Stocks For Your Watchlist This Week
Biotechnology stocks, also known as biotech stocks, are shares in publicly traded companies that are involved in the medical and agricultural applications of biotechnology. Biotech stocks can be volatile, but they have the potential to offer investors significant returns. T... | Best Biotech Stocks To Buy [Or Sell] Now AbbVie Inc. (NYSE: ABBV) Pfizer Inc. (NYSE: PFE) Biogen Inc. (NASDAQ: BIIB) Amgen Inc. (NASDAQ: AMGN) AbbVie (ABBV Stock) First, AbbVie Inc. (ABBV) is a research-based biopharmaceutical company. In brief, AbbVie discovers, develops, and markets both biologic and small molecule d... | Best Biotech Stocks To Buy [Or Sell] Now AbbVie Inc. (NYSE: ABBV) Pfizer Inc. (NYSE: PFE) Biogen Inc. (NASDAQ: BIIB) Amgen Inc. (NASDAQ: AMGN) AbbVie (ABBV Stock) First, AbbVie Inc. (ABBV) is a research-based biopharmaceutical company. In brief, AbbVie discovers, develops, and markets both biologic and small molecule d... | Best Biotech Stocks To Buy [Or Sell] Now AbbVie Inc. (NYSE: ABBV) Pfizer Inc. (NYSE: PFE) Biogen Inc. (NASDAQ: BIIB) Amgen Inc. (NASDAQ: AMGN) AbbVie (ABBV Stock) First, AbbVie Inc. (ABBV) is a research-based biopharmaceutical company. In brief, AbbVie discovers, develops, and markets both biologic and small molecule d... | Best Biotech Stocks To Buy [Or Sell] Now AbbVie Inc. (NYSE: ABBV) Pfizer Inc. (NYSE: PFE) Biogen Inc. (NASDAQ: BIIB) Amgen Inc. (NASDAQ: AMGN) AbbVie (ABBV Stock) First, AbbVie Inc. (ABBV) is a research-based biopharmaceutical company. Getting straight to it, AbbVie reported revenue for the quarter of $14.6 billion. In... |
23,137 | 2022-09-09 00:00:00 UTC | Daily Dividend Report: VAC,ABBV,AMAT,KRC,VICI | ABBV | https://www.nasdaq.com/articles/daily-dividend-report%3A-vacabbvamatkrcvici | null | null | Marriott Vacations Worldwide today announced its board of directors authorized a quarterly cash dividend of $0.62 per share of common stock. The dividend is payable on or around October 6, 2022 to shareholders of record as of the close of business on September 22, 2022.
The board of directors of AbbVie today declared a... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.41 per share. Since the company's inception in 2013, AbbVie has increased its dividend by more than 250 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend fo... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.41 per share. Since the company's inception in 2013, AbbVie has increased its dividend by more than 250 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend fo... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.41 per share. Since the company's inception in 2013, AbbVie has increased its dividend by more than 250 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend fo... | The board of directors of AbbVie today declared a quarterly cash dividend of $1.41 per share. Since the company's inception in 2013, AbbVie has increased its dividend by more than 250 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend fo... |
23,138 | 2022-09-09 00:00:00 UTC | Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now? | ABBV | https://www.nasdaq.com/articles/is-most-watched-stock-abbvie-inc.-abbv-worth-betting-on-now-1 | null | null | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this drugmaker have returned -1.1% over the past month versus the Zacks S&P 500 composite's -3.1% change. The Zacks ... | Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie be... | Last Reported Results and Surprise History AbbVie reported revenues of $14.58 billion in the last reported quarter, representing a year-over-year change of +4.5%. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost... | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost 2.3% over this period. For the current quarter, AbbVie is expected to post earnings of $3.59 per share, indicating a change of +7.8% from the year-ago quarter. | For the next fiscal year, the consensus earnings estimate of $11.80 indicates a change of -15.1% from what AbbVie is expected to report a year ago. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost 2.3% over this... |
23,139 | 2022-09-09 00:00:00 UTC | Revance (RVNC) Gets FDA Nod for Anti-Wrinkle Product, Stock Up | ABBV | https://www.nasdaq.com/articles/revance-rvnc-gets-fda-nod-for-anti-wrinkle-product-stock-up | null | null | Revance Therapeutics RVNC shares were up 21.6% on Thursday after it announced FDA approval for its DaxibotulinumtoxinA for Injection (DAXI), a rival treatment to AbbVie’s ABBV blockbuster Botox injections for improving frown lines.
DAXI will be marketed as Daxxify for injection for the temporary improvement of moderate... | Revance Therapeutics RVNC shares were up 21.6% on Thursday after it announced FDA approval for its DaxibotulinumtoxinA for Injection (DAXI), a rival treatment to AbbVie’s ABBV blockbuster Botox injections for improving frown lines. AbbVie’s Botox is approved for several therapeutic and aesthetic indications. AbbVie acq... | Revance Therapeutics RVNC shares were up 21.6% on Thursday after it announced FDA approval for its DaxibotulinumtoxinA for Injection (DAXI), a rival treatment to AbbVie’s ABBV blockbuster Botox injections for improving frown lines. AbbVie’s Botox is approved for several therapeutic and aesthetic indications. AbbVie acq... | Revance Therapeutics RVNC shares were up 21.6% on Thursday after it announced FDA approval for its DaxibotulinumtoxinA for Injection (DAXI), a rival treatment to AbbVie’s ABBV blockbuster Botox injections for improving frown lines. AbbVie’s Botox is approved for several therapeutic and aesthetic indications. AbbVie acq... | AbbVie’s Botox is approved for several therapeutic and aesthetic indications. Revance Therapeutics RVNC shares were up 21.6% on Thursday after it announced FDA approval for its DaxibotulinumtoxinA for Injection (DAXI), a rival treatment to AbbVie’s ABBV blockbuster Botox injections for improving frown lines. AbbVie acq... |
23,140 | 2022-09-08 00:00:00 UTC | Exxon (XOM), AbbVie (ABBV): Befriend These 2 Dividend Aristocrat Stocks | ABBV | https://www.nasdaq.com/articles/exxon-xom-abbvie-abbv%3A-befriend-these-2-dividend-aristocrat-stocks | null | null | Exxon Mobil (NYSE:XOM) and AbbVie (NYSE:ABBV) are popular dividend aristocrats that have increased their annual dividend payments for decades. Both companies are a member of the S&P Dividend Aristocrats Index. The index tracks companies that have annually increased their dividend for at least 25 years in a row. Strong ... | TipRanks data shows that hedge funds are apprehensive about the company, as they sold 1.1 million shares of ABBV stock in the last quarter. Giving investors more reasons to invest in them, Exxon and AbbVie have managed to beat the S&P 500 Dividend Aristocrats index by gaining 52.8% and 5.4%, respectively, in the year-t... | Exxon Mobil (NYSE:XOM) and AbbVie (NYSE:ABBV) are popular dividend aristocrats that have increased their annual dividend payments for decades. AbbVie (NYSE:ABBV) Stock Abbvie has an impressive track record of 50 consecutive years of dividend increases. Adding to the optimism, ABBV stock’s average price target of $160.5... | Exxon Mobil (NYSE:XOM) and AbbVie (NYSE:ABBV) are popular dividend aristocrats that have increased their annual dividend payments for decades. Let’s delve deeper into why Exxon and AbbVie could be the safety plugs for your investment portfolio in the rest of 2022: Exxon Mobil (NYSE:XOM) Stock Having had a glorious reco... | Let’s delve deeper into why Exxon and AbbVie could be the safety plugs for your investment portfolio in the rest of 2022: Exxon Mobil (NYSE:XOM) Stock Having had a glorious record of raising annual dividends for 39 straight years, Exxon had distributed $7.6 billion to shareholders, including dividends worth around $3.7... |
23,141 | 2022-09-08 00:00:00 UTC | 7 S&P 500 Stocks to Buy With Superior Fundamentals | ABBV | https://www.nasdaq.com/articles/7-sp-500-stocks-to-buy-with-superior-fundamentals | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Starting the session following Labor Day weekend in the red, it’s clear that even so-called S&P 500 stocks to buy are feeling the heat. Toward the end of August, Federal Reserve chair Jerome Powell presented a less-than-encouraging picture for future moneta... | Ticker Company Price CVX Chevron $154.16 ABBV AbbVie $140.06 PEP PepsiCo $171.71 COST CostCo $527.46 GS Goldman Sachs $332.67 WM Waste Management $173.00 Chevron (CVX) Source: Jeff Whyte / Shutterstock.com Earlier this year, Chevron (NYSE:CVX) and other oil and natural gas firms enjoyed the most cynical of tailwinds. A... | Ticker Company Price CVX Chevron $154.16 ABBV AbbVie $140.06 PEP PepsiCo $171.71 COST CostCo $527.46 GS Goldman Sachs $332.67 WM Waste Management $173.00 Chevron (CVX) Source: Jeff Whyte / Shutterstock.com Earlier this year, Chevron (NYSE:CVX) and other oil and natural gas firms enjoyed the most cynical of tailwinds. A... | Ticker Company Price CVX Chevron $154.16 ABBV AbbVie $140.06 PEP PepsiCo $171.71 COST CostCo $527.46 GS Goldman Sachs $332.67 WM Waste Management $173.00 Chevron (CVX) Source: Jeff Whyte / Shutterstock.com Earlier this year, Chevron (NYSE:CVX) and other oil and natural gas firms enjoyed the most cynical of tailwinds. A... | Ticker Company Price CVX Chevron $154.16 ABBV AbbVie $140.06 PEP PepsiCo $171.71 COST CostCo $527.46 GS Goldman Sachs $332.67 WM Waste Management $173.00 Chevron (CVX) Source: Jeff Whyte / Shutterstock.com Earlier this year, Chevron (NYSE:CVX) and other oil and natural gas firms enjoyed the most cynical of tailwinds. A... |
23,142 | 2022-09-08 00:00:00 UTC | U.S. FDA approves Revance's wrinkle treatment | ABBV | https://www.nasdaq.com/articles/u.s.-fda-approves-revances-wrinkle-treatment-0 | null | null | Adds details
Sept 7 (Reuters) - Revance Therapeutics RVNC.O said on Thursday it had received the U.S. Food and Drug Administration's approval for its injection to treat wrinkles that appear as people become older.
The company said the treatment, which will be sold under the brand Daxxify, has the ability to address the... | Daxxify could be a potential rival to AbbVie's ABBV.NBotox in the $3.2 billion U.S. facial injectables market. Adds details Sept 7 (Reuters) - Revance Therapeutics RVNC.O said on Thursday it had received the U.S. Food and Drug Administration's approval for its injection to treat wrinkles that appear as people become ol... | Daxxify could be a potential rival to AbbVie's ABBV.NBotox in the $3.2 billion U.S. facial injectables market. Adds details Sept 7 (Reuters) - Revance Therapeutics RVNC.O said on Thursday it had received the U.S. Food and Drug Administration's approval for its injection to treat wrinkles that appear as people become ol... | Daxxify could be a potential rival to AbbVie's ABBV.NBotox in the $3.2 billion U.S. facial injectables market. Adds details Sept 7 (Reuters) - Revance Therapeutics RVNC.O said on Thursday it had received the U.S. Food and Drug Administration's approval for its injection to treat wrinkles that appear as people become ol... | Daxxify could be a potential rival to AbbVie's ABBV.NBotox in the $3.2 billion U.S. facial injectables market. Adds details Sept 7 (Reuters) - Revance Therapeutics RVNC.O said on Thursday it had received the U.S. Food and Drug Administration's approval for its injection to treat wrinkles that appear as people become ol... |
23,143 | 2022-09-08 00:00:00 UTC | SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma | ABBV | https://www.nasdaq.com/articles/springworks-swtx-gsk-expand-deal-to-treat-multiple-myeloma | null | null | SpringWorks Therapeutics, Inc. SWTX expanded its existing clinical collaboration agreement with GSK GSK. The partnership is evaluating the combination of SpringWorks’ investigational oral gamma secretase inhibitor, nirogacestat, with GSK’s anti-BCMA antibody-drug conjugate, Blenrep, in patients with multiple myeloma (M... | Apart from GSK, the company has also entered into a similar agreement with AbbVie ABBV and Regeneron REGN, evaluating the combination of nirogacestat and the AbbVie and Regeneron’s respective BCMA-specific antibodies for treating relapsed/refractory MM. SpringWorks had entered into a collaboration with AbbVie last Dece... | Apart from GSK, the company has also entered into a similar agreement with AbbVie ABBV and Regeneron REGN, evaluating the combination of nirogacestat and the AbbVie and Regeneron’s respective BCMA-specific antibodies for treating relapsed/refractory MM. SpringWorks had entered into a collaboration with AbbVie last Dece... | Apart from GSK, the company has also entered into a similar agreement with AbbVie ABBV and Regeneron REGN, evaluating the combination of nirogacestat and the AbbVie and Regeneron’s respective BCMA-specific antibodies for treating relapsed/refractory MM. SpringWorks had entered into a collaboration with AbbVie last Dece... | Apart from GSK, the company has also entered into a similar agreement with AbbVie ABBV and Regeneron REGN, evaluating the combination of nirogacestat and the AbbVie and Regeneron’s respective BCMA-specific antibodies for treating relapsed/refractory MM. SpringWorks had entered into a collaboration with AbbVie last Dece... |
23,144 | 2022-09-08 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABBV | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-44 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | AbbVie Inc (Symbol: ABBV) $138.71 $163.56 17.92% Procter & Gamble Company (Symbol: PG) $137.68 $161.82 17.53% Johnson & Johnson (Symbol: JNJ) $164.07 $186.33 13.57% California Water Service Group (Symbol: CWT) $58.80 $64.50 9.69% Berkley Corp (Symbol: WRB) $66.86 $72.67 8.68% The average 12-month analyst targets are on... | AbbVie Inc (Symbol: ABBV) $138.71 $163.56 17.92% Procter & Gamble Company (Symbol: PG) $137.68 $161.82 17.53% Johnson & Johnson (Symbol: JNJ) $164.07 $186.33 13.57% California Water Service Group (Symbol: CWT) $58.80 $64.50 9.69% Berkley Corp (Symbol: WRB) $66.86 $72.67 8.68% The average 12-month analyst targets are on... | AbbVie Inc (Symbol: ABBV) $138.71 $163.56 17.92% Procter & Gamble Company (Symbol: PG) $137.68 $161.82 17.53% Johnson & Johnson (Symbol: JNJ) $164.07 $186.33 13.57% California Water Service Group (Symbol: CWT) $58.80 $64.50 9.69% Berkley Corp (Symbol: WRB) $66.86 $72.67 8.68% The average 12-month analyst targets are on... | AbbVie Inc (Symbol: ABBV) $138.71 $163.56 17.92% Procter & Gamble Company (Symbol: PG) $137.68 $161.82 17.53% Johnson & Johnson (Symbol: JNJ) $164.07 $186.33 13.57% California Water Service Group (Symbol: CWT) $58.80 $64.50 9.69% Berkley Corp (Symbol: WRB) $66.86 $72.67 8.68% The average 12-month analyst targets are on... |
23,145 | 2022-09-07 00:00:00 UTC | Ironwood's (IRWD) Functional Constipation Study in Kids Succeeds | ABBV | https://www.nasdaq.com/articles/ironwoods-irwd-functional-constipation-study-in-kids-succeeds | null | null | Ironwood Pharmaceuticals IRWD recently announced positive top-line data from its phase III study evaluating its critical medicine Linzess (linaclotide) in pediatric patients six to 17 years of age with functional constipation (“FC”).
Linzess, developed by Ironwood and its partner AbbVie ABBV, is the sole commercial pro... | With the positive top-line results of the late-stage study evaluating linaclotide in FC, Ironwood, with its partnerAbbVieintends to move forward with a potential submission of a supplemental new drug application (sNDA) to the FDA. Linzess, developed by Ironwood and its partner AbbVie ABBV, is the sole commercial produc... | Linzess, developed by Ironwood and its partner AbbVie ABBV, is the sole commercial product in Ironwood’s portfolio. With the positive top-line results of the late-stage study evaluating linaclotide in FC, Ironwood, with its partnerAbbVieintends to move forward with a potential submission of a supplemental new drug appl... | Linzess, developed by Ironwood and its partner AbbVie ABBV, is the sole commercial product in Ironwood’s portfolio. With the positive top-line results of the late-stage study evaluating linaclotide in FC, Ironwood, with its partnerAbbVieintends to move forward with a potential submission of a supplemental new drug appl... | Linzess, developed by Ironwood and its partner AbbVie ABBV, is the sole commercial product in Ironwood’s portfolio. With the positive top-line results of the late-stage study evaluating linaclotide in FC, Ironwood, with its partnerAbbVieintends to move forward with a potential submission of a supplemental new drug appl... |
23,146 | 2022-09-05 00:00:00 UTC | 3 Things You Shouldn't Do if the Stock Market Crashes | ABBV | https://www.nasdaq.com/articles/3-things-you-shouldnt-do-if-the-stock-market-crashes-2 | null | null | With the market in a jittery mood thanks to ongoing inflation, interest rate hike mania, and geopolitical instability, nobody can blame investors who are wringing their hands anxiously in anticipation of a potential market crash. Thankfully, the chances of a crash happening are too difficult to determine with any certa... | Let's examine AbbVie's (NYSE: ABBV) performance during the coronavirus crash in March 2020 as an example. ^SPX data by YCharts As you can see, AbbVie's shares took a beating during the crash, as did the market. There's absolutely no guarantee that every stock will behave the same as AbbVie's did during every market cra... | For example, let's say before the pandemic you held AMC Entertainment (NYSE: AMC) for exposure to the entertainment industry in the same portfolio as your AbbVie shares. Let's examine AbbVie's (NYSE: ABBV) performance during the coronavirus crash in March 2020 as an example. ^SPX data by YCharts As you can see, AbbVie'... | Let's examine AbbVie's (NYSE: ABBV) performance during the coronavirus crash in March 2020 as an example. ^SPX data by YCharts As you can see, AbbVie's shares took a beating during the crash, as did the market. There's absolutely no guarantee that every stock will behave the same as AbbVie's did during every market cra... | Let's examine AbbVie's (NYSE: ABBV) performance during the coronavirus crash in March 2020 as an example. ^SPX data by YCharts As you can see, AbbVie's shares took a beating during the crash, as did the market. There's absolutely no guarantee that every stock will behave the same as AbbVie's did during every market cra... |
23,147 | 2022-09-05 00:00:00 UTC | 3 Dividend Aristocrats to Buy That Could Beat the Market Over the Next 10 Years | ABBV | https://www.nasdaq.com/articles/3-dividend-aristocrats-to-buy-that-could-beat-the-market-over-the-next-10-years | null | null | Nobility isn't necessarily all it's cracked up to be. That's definitely the case with the nobility of dividend stocks -- Dividend Aristocrats. These members of the S&P 500 have increased their dividends for at least 25 consecutive years. But they aren't always the biggest winners for investors.
Over the past three-year... | With AbbVie's shares trading below 9.8 times expected earnings, this stock could easily be a market-beater over the next 10 years. AbbVie AbbVie (NYSE: ABBV) isn't just a Dividend Aristocrat; it's also a Dividend King. AbbVie hasn't depended only on its dividends to reward investors in recent years, though. | AbbVie AbbVie (NYSE: ABBV) isn't just a Dividend Aristocrat; it's also a Dividend King. AbbVie hasn't depended only on its dividends to reward investors in recent years, though. You might think that the loss of exclusivity for Humira next year could put AbbVie at a disadvantage. | AbbVie AbbVie (NYSE: ABBV) isn't just a Dividend Aristocrat; it's also a Dividend King. AbbVie hasn't depended only on its dividends to reward investors in recent years, though. You might think that the loss of exclusivity for Humira next year could put AbbVie at a disadvantage. | AbbVie AbbVie (NYSE: ABBV) isn't just a Dividend Aristocrat; it's also a Dividend King. AbbVie hasn't depended only on its dividends to reward investors in recent years, though. You might think that the loss of exclusivity for Humira next year could put AbbVie at a disadvantage. |
23,148 | 2022-09-04 00:00:00 UTC | 2 Top Biotech Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/2-top-biotech-stocks-to-buy-right-now-4 | null | null | The biotech sector has brought its share of big gains to investors' portfolios, from coronavirus success stories such as Moderna to long-established names like Biogen. Moderna, the maker of a top-selling coronavirus vaccine, has climbed more than 600% over the past two and a half years. Biogen has advanced 11,000% sinc... | AbbVie The bad news for AbbVie (NYSE: ABBV) is that its major blockbuster drug, the rheumatoid arthritis treatment Humira, will face competition in the U.S. as of next year. The good news is that the rest of AbbVie's immunology portfolio may eventually compensate for the loss. AbbVie also has a strong aesthetics portfo... | AbbVie The bad news for AbbVie (NYSE: ABBV) is that its major blockbuster drug, the rheumatoid arthritis treatment Humira, will face competition in the U.S. as of next year. The good news is that the rest of AbbVie's immunology portfolio may eventually compensate for the loss. AbbVie also has a strong aesthetics portfo... | AbbVie The bad news for AbbVie (NYSE: ABBV) is that its major blockbuster drug, the rheumatoid arthritis treatment Humira, will face competition in the U.S. as of next year. The good news is that the rest of AbbVie's immunology portfolio may eventually compensate for the loss. AbbVie also has a strong aesthetics portfo... | AbbVie The bad news for AbbVie (NYSE: ABBV) is that its major blockbuster drug, the rheumatoid arthritis treatment Humira, will face competition in the U.S. as of next year. The good news is that the rest of AbbVie's immunology portfolio may eventually compensate for the loss. AbbVie also has a strong aesthetics portfo... |
23,149 | 2022-09-03 00:00:00 UTC | 3 Great Dividend Stocks to Buy in September | ABBV | https://www.nasdaq.com/articles/3-great-dividend-stocks-to-buy-in-september | null | null | Sure, the stock market remains volatile. But dividend stocks often provide more stability than most other stocks. They also pay you to wait for the market choppiness to end.
We asked three Motley Fool contributors to pick dividend stocks to buy in September. Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (N... | Although the company's crown jewel, immunology medicine Humira, faces biosimilar competition next year, AbbVie has earned many more approvals and acquired other products to prepare for these challengers. AbbVie's solid pipeline ensures it will expand its revenue base and continue delivering strong financial results lon... | A dividend stock for all seasons Prosper Junior Bakiny (AbbVie): Pharma giant AbbVie boasts practically all the characteristics of an outstanding dividend stock, including a stable business with increasing revenue and earnings, solid growth avenues, a juicy yield, a conservative payout ratio, and of course, an impressi... | A dividend stock for all seasons Prosper Junior Bakiny (AbbVie): Pharma giant AbbVie boasts practically all the characteristics of an outstanding dividend stock, including a stable business with increasing revenue and earnings, solid growth avenues, a juicy yield, a conservative payout ratio, and of course, an impressi... | Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ). A dividend stock for all seasons Prosper Junior Bakiny (AbbVie): Pharma giant AbbVie boasts practically all the characteristics of an outstanding dividend stock, including a stable business with increasing reve... |
23,150 | 2022-09-01 00:00:00 UTC | Is Humira Maker A Better Bet Over Merck Stock? | ABBV | https://www.nasdaq.com/articles/is-humira-maker-a-better-bet-over-merck-stock | null | null | We believe that AbbVie stock (NYSE: ABBV) is currently a better pick than its peer Merck stock (NYSE: MRK), given its better growth prospects. Both companies are comparable in valuation, with AbbVie trading at 4.2x, trailing revenues, and Merck trading at 3.9x.
If we look at stock returns, Merck’s 14% growth this year ... | We compare a slew of factors such as historical revenue growth, returns, and valuation multiple in an interactive dashboard analysis of AbbVie vs. Merck: Which Stock Is A Better Bet? That said, AbbVie is prepared to combat this biosimilar impact with its Allergan acquisition in 2020, giving it access to Botox, a multi-... | It points to a CAGR of 8.6% for AbbVie, compared to a 1.6% CAGR for Merck, based on Trefis Machine Learning analysis. The table below summarizes our revenue and return expectations for AbbVie and Merck over the next three years and points to an expected return of 33% for AbbVie over this period vs. a 14% expected retur... | If we look at stock returns, Merck’s 14% growth this year is much better than the 0.2% return for AbbVie stock and -16% returns for the broader S&P 500 index. We compare a slew of factors such as historical revenue growth, returns, and valuation multiple in an interactive dashboard analysis of AbbVie vs. Merck: Which S... | If we look at stock returns, Merck’s 14% growth this year is much better than the 0.2% return for AbbVie stock and -16% returns for the broader S&P 500 index. We compare a slew of factors such as historical revenue growth, returns, and valuation multiple in an interactive dashboard analysis of AbbVie vs. Merck: Which S... |
23,151 | 2022-09-01 00:00:00 UTC | Thursday Sector Leaders: Utilities, Healthcare | ABBV | https://www.nasdaq.com/articles/thursday-sector-leaders%3A-utilities-healthcare-3 | null | null | Looking at the sectors faring best as of midday Thursday, shares of Utilities companies are outperforming other sectors, up 1.3%. Within that group, American Electric Power Co Inc (Symbol: AEP) and Southern Company (Symbol: SO) are two of the day's stand-outs, showing a gain of 2.5% and 2.2%, respectively. Among utilit... | Combined, COO and ABBV make up approximately 5.4% of the underlying holdings of XLV. Among large Healthcare stocks, Cooper Companies, Inc. (Symbol: COO) and AbbVie Inc (Symbol: ABBV) are the most notable, showing a gain of 3.0% and 2.8%, respectively. Cooper Companies, Inc., meanwhile, is down 29.35% year-to-date, and ... | Among large Healthcare stocks, Cooper Companies, Inc. (Symbol: COO) and AbbVie Inc (Symbol: ABBV) are the most notable, showing a gain of 3.0% and 2.8%, respectively. Cooper Companies, Inc., meanwhile, is down 29.35% year-to-date, and AbbVie Inc is up 5.25% year-to-date. Combined, COO and ABBV make up approximately 5.4... | Among large Healthcare stocks, Cooper Companies, Inc. (Symbol: COO) and AbbVie Inc (Symbol: ABBV) are the most notable, showing a gain of 3.0% and 2.8%, respectively. Cooper Companies, Inc., meanwhile, is down 29.35% year-to-date, and AbbVie Inc is up 5.25% year-to-date. Combined, COO and ABBV make up approximately 5.4... | Among large Healthcare stocks, Cooper Companies, Inc. (Symbol: COO) and AbbVie Inc (Symbol: ABBV) are the most notable, showing a gain of 3.0% and 2.8%, respectively. Cooper Companies, Inc., meanwhile, is down 29.35% year-to-date, and AbbVie Inc is up 5.25% year-to-date. Combined, COO and ABBV make up approximately 5.4... |
23,152 | 2022-09-01 00:00:00 UTC | Interesting ABBV Put And Call Options For October 14th | ABBV | https://www.nasdaq.com/articles/interesting-abbv-put-and-call-options-for-october-14th | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the October 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new October 14th contracts and identified one put and one call contract of particular interest.
The put c... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $140.00 strike highlighted in red: Considering the fact that the $140.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $130.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $140.00 strike price has a current bid of $2.74. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new October 14th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $140.00 strike highlighted in red: Consid... |
23,153 | 2022-09-01 00:00:00 UTC | 3 Dividend Stocks to Buy in September for Passive Income Generation | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-to-buy-in-september-for-passive-income-generation | null | null | Do you like getting paid to do practically nothing? I thought so.
Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they... | AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. AbbVie AbbVie (NYSE: ABBV) was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that co... | AbbVie AbbVie (NYSE: ABBV) was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher. AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. | AbbVie AbbVie (NYSE: ABBV) was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher. AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. | AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. AbbVie AbbVie (NYSE: ABBV) was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher. |
23,154 | 2022-08-31 00:00:00 UTC | Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study | ABBV | https://www.nasdaq.com/articles/curis-cris-gets-fda-nod-to-partly-resume-leukemia-study | null | null | Curis, Inc. CRIS announced that it has received a notification from the FDA, wherein the regulatory body allowed the company to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study.
The open-label, dose-escalation phase I/II study is evaluating Curis’ IRAK4 kinase inhibitor, e... | The dose-escalating phase I/II study is evaluating emavusertib for treating patients with B-cell malignancies, both as a monotherapy and in combination with Johnson & Johnson JNJ/AbbVie’s ABBV BTK inhibitor, Imbruvica (ibrutinib), in patients with relapsed or refractory (R/R) hematologic malignancies, such as non-Hodgk... | The dose-escalating phase I/II study is evaluating emavusertib for treating patients with B-cell malignancies, both as a monotherapy and in combination with Johnson & Johnson JNJ/AbbVie’s ABBV BTK inhibitor, Imbruvica (ibrutinib), in patients with relapsed or refractory (R/R) hematologic malignancies, such as non-Hodgk... | The dose-escalating phase I/II study is evaluating emavusertib for treating patients with B-cell malignancies, both as a monotherapy and in combination with Johnson & Johnson JNJ/AbbVie’s ABBV BTK inhibitor, Imbruvica (ibrutinib), in patients with relapsed or refractory (R/R) hematologic malignancies, such as non-Hodgk... | AbbVie and J&J are conducting several studies on Imbruvica to evaluate the drug alone or in combination in different patient segments. The dose-escalating phase I/II study is evaluating emavusertib for treating patients with B-cell malignancies, both as a monotherapy and in combination with Johnson & Johnson JNJ/AbbVie... |
23,155 | 2022-08-31 00:00:00 UTC | HDV, ABBV, VZ, PM: Large Inflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/hdv-abbv-vz-pm%3A-large-inflows-detected-at-etf | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core High Dividend ETF (Symbol: HDV) where we have detected an approximate $86.4 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 119,800,000... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.1%, Verizon Communications Inc (Symbol: VZ) is off about 0.7%, and Philip Morris International Inc (Symbol: PM) is higher by about 0.5%. For a complete list of holdings, visit the HDV Holdings page » The chart bel... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.1%, Verizon Communications Inc (Symbol: VZ) is off about 0.7%, and Philip Morris International Inc (Symbol: PM) is higher by about 0.5%. For a complete list of holdings, visit the HDV Holdings page » The chart bel... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.1%, Verizon Communications Inc (Symbol: VZ) is off about 0.7%, and Philip Morris International Inc (Symbol: PM) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the univers... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.1%, Verizon Communications Inc (Symbol: VZ) is off about 0.7%, and Philip Morris International Inc (Symbol: PM) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the univers... |
23,156 | 2022-08-30 00:00:00 UTC | Amgen (AMGN) Outperforms Industry Year to Date: What's Next? | ABBV | https://www.nasdaq.com/articles/amgen-amgn-outperforms-industry-year-to-date%3A-whats-next | null | null | Amgen AMGN has a diverse and growing portfolio of medicines in large therapeutic categories that it expects will help it drive growth through the end of the decade despite a declining pricing environment.
Amgen stock has risen 6.4% this year so far against a decrease of 23.6% for the industry.
Image Source: Zacks Inve... | Amgen markets Kanjinti (a biosimilar of Roche’s [RHHBY] Herceptin) and Mvasi (a biosimilar of Roche’s Avastin) in the United States and Amgevita (a biosimilar of AbbVie’s [ABBV] Humira), Kanjinti and Mvasi outside the United States. In the United States, AbbVie’s Humira biosimilar, Amjevita is expected to be launched i... | Amgen markets Kanjinti (a biosimilar of Roche’s [RHHBY] Herceptin) and Mvasi (a biosimilar of Roche’s Avastin) in the United States and Amgevita (a biosimilar of AbbVie’s [ABBV] Humira), Kanjinti and Mvasi outside the United States. In the United States, AbbVie’s Humira biosimilar, Amjevita is expected to be launched i... | Amgen markets Kanjinti (a biosimilar of Roche’s [RHHBY] Herceptin) and Mvasi (a biosimilar of Roche’s Avastin) in the United States and Amgevita (a biosimilar of AbbVie’s [ABBV] Humira), Kanjinti and Mvasi outside the United States. In the United States, AbbVie’s Humira biosimilar, Amjevita is expected to be launched i... | Amgen markets Kanjinti (a biosimilar of Roche’s [RHHBY] Herceptin) and Mvasi (a biosimilar of Roche’s Avastin) in the United States and Amgevita (a biosimilar of AbbVie’s [ABBV] Humira), Kanjinti and Mvasi outside the United States. In the United States, AbbVie’s Humira biosimilar, Amjevita is expected to be launched i... |
23,157 | 2022-08-29 00:00:00 UTC | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-is-attracting-investor-attention%3A-here-is-what-you-should-know-0 | null | null | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this drugmaker have returned -5%, compared to the Zacks S&P 500 composite's +3.7% change. Durin... | Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industr... | For the next fiscal year, the consensus earnings estimate of $11.80 indicates a change of -15.1% from what AbbVie is expected to report a year ago. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has l... | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie... | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has lost 6.2%. For the current quarter, AbbVie is expected to post earnings of $3.59 per share, indicating a change of +7.8% from the year-ago quarter. |
23,158 | 2022-08-29 00:00:00 UTC | The Zacks Analyst Blog Highlights Novartis, J&J, AbbVie, Merck and Pfizer | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-novartis-jj-abbvie-merck-and-pfizer | null | null | For Immediate Release
Chicago, IL – August 29, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novartis NVS, J&J JNJ, AbbV... | The FDA granted approval to J&J and AbbVie's cancer drug Imbruvica for a pediatric indication and gave Fast Track designation to Merck's investigational anticoagulant therapy, MK-2060. Stocks recently featured in the blog include: Novartis NVS, J&J JNJ, AbbVie's ABBV, Merck's MRK and Pfizer PFE. FDA Approves J&J/AbbVie... | Stocks recently featured in the blog include: Novartis NVS, J&J JNJ, AbbVie's ABBV, Merck's MRK and Pfizer PFE. The FDA granted approval to J&J and AbbVie's cancer drug Imbruvica for a pediatric indication and gave Fast Track designation to Merck's investigational anticoagulant therapy, MK-2060. FDA Approves J&J/AbbVie... | Stocks recently featured in the blog include: Novartis NVS, J&J JNJ, AbbVie's ABBV, Merck's MRK and Pfizer PFE. The FDA granted approval to J&J and AbbVie's cancer drug Imbruvica for a pediatric indication and gave Fast Track designation to Merck's investigational anticoagulant therapy, MK-2060. FDA Approves J&J/AbbVie... | Stocks recently featured in the blog include: Novartis NVS, J&J JNJ, AbbVie's ABBV, Merck's MRK and Pfizer PFE. The FDA granted approval to J&J and AbbVie's cancer drug Imbruvica for a pediatric indication and gave Fast Track designation to Merck's investigational anticoagulant therapy, MK-2060. FDA Approves J&J/AbbVie... |
23,159 | 2022-08-26 00:00:00 UTC | Why Dividend Growth Stocks Should Be Part of Your Retirement Plan | ABBV | https://www.nasdaq.com/articles/why-dividend-growth-stocks-should-be-part-of-your-retirement-plan | null | null | If you are saving for retirement, you should aim to include not just any dividend stocks, but stocks that regularly increase their payouts over time. They can add some important stability to your portfolio as they are normally safe businesses to hold and can pay off in the long haul -- just through their dividend payme... | Healthcare company AbbVie (NYSE: ABBV) is an example of a safe dividend stock to buy and hold, as the drugmaker has posted a profit margin of 22% over the past 12 months. Today, AbbVie pays a dividend yield of 4%. If the company were to continue growing its dividend payments by 8% per year, here's how much dividend inc... | Healthcare company AbbVie (NYSE: ABBV) is an example of a safe dividend stock to buy and hold, as the drugmaker has posted a profit margin of 22% over the past 12 months. Today, AbbVie pays a dividend yield of 4%. If the company were to continue growing its dividend payments by 8% per year, here's how much dividend inc... | Healthcare company AbbVie (NYSE: ABBV) is an example of a safe dividend stock to buy and hold, as the drugmaker has posted a profit margin of 22% over the past 12 months. Today, AbbVie pays a dividend yield of 4%. If the company were to continue growing its dividend payments by 8% per year, here's how much dividend inc... | If the company were to continue growing its dividend payments by 8% per year, here's how much dividend income an investor would be collecting on a $25,000 investment in AbbVie. Healthcare company AbbVie (NYSE: ABBV) is an example of a safe dividend stock to buy and hold, as the drugmaker has posted a profit margin of 2... |
23,160 | 2022-08-26 00:00:00 UTC | Pharma Stock Roundup: NVS to Spin Off Sandoz; JNJ, MRK, ABBV's FDA Updates | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-nvs-to-spin-off-sandoz-jnj-mrk-abbvs-fda-updates | null | null | This week, Novartis NVS announced the planned spin-off of its generics division, Sandoz, to create a leading European generics company. The FDA granted approval to J&J JNJ and AbbVie’s ABBV cancer drug Imbruvica for a pediatric indication and gave Fast Track designation to Merck’s MRK investigational anticoagulant ther... | The FDA granted approval to J&J JNJ and AbbVie’s ABBV cancer drug Imbruvica for a pediatric indication and gave Fast Track designation to Merck’s MRK investigational anticoagulant therapy, MK-2060. FDA Approves J&J/AbbVie’s Imbruvica for Pediatric cGVHD: The FDA approved J&J and AbbVie’s cancer blockbuster medicine, Im... | The FDA granted approval to J&J JNJ and AbbVie’s ABBV cancer drug Imbruvica for a pediatric indication and gave Fast Track designation to Merck’s MRK investigational anticoagulant therapy, MK-2060. FDA Approves J&J/AbbVie’s Imbruvica for Pediatric cGVHD: The FDA approved J&J and AbbVie’s cancer blockbuster medicine, Im... | The FDA granted approval to J&J JNJ and AbbVie’s ABBV cancer drug Imbruvica for a pediatric indication and gave Fast Track designation to Merck’s MRK investigational anticoagulant therapy, MK-2060. FDA Approves J&J/AbbVie’s Imbruvica for Pediatric cGVHD: The FDA approved J&J and AbbVie’s cancer blockbuster medicine, Im... | The FDA granted approval to J&J JNJ and AbbVie’s ABBV cancer drug Imbruvica for a pediatric indication and gave Fast Track designation to Merck’s MRK investigational anticoagulant therapy, MK-2060. FDA Approves J&J/AbbVie’s Imbruvica for Pediatric cGVHD: The FDA approved J&J and AbbVie’s cancer blockbuster medicine, Im... |
23,161 | 2022-08-25 00:00:00 UTC | Do Warren Buffett's Recent Moves Spell Doom for This Group of Stocks? | ABBV | https://www.nasdaq.com/articles/do-warren-buffetts-recent-moves-spell-doom-for-this-group-of-stocks | null | null | Warren Buffett is frequently called the "Oracle of Omaha." An oracle, by definition, is something that provides wise counsel and often foretells the future. Buffett's uncanny ability to pick stocks that beat the market over the long term seems to justify his nickname.
So when the Oracle of Omaha sells a specific group ... | In the first quarter of this year, Berkshire sold all of its remaining shares of two other pharma stocks -- AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to listen. * They just revealed what they believe are... | See the 10 stocks *Stock Advisor returns as of August 17, 2022 Keith Speights has positions in AbbVie, Berkshire Hathaway (B shares), Bristol Myers Squibb, and Pfizer. In the first quarter of this year, Berkshire sold all of its remaining shares of two other pharma stocks -- AbbVie (NYSE: ABBV) and Bristol Myers Squibb... | In the first quarter of this year, Berkshire sold all of its remaining shares of two other pharma stocks -- AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). See the 10 stocks *Stock Advisor returns as of August 17, 2022 Keith Speights has positions in AbbVie, Berkshire Hathaway (B shares), Bristol Myers Squibb... | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! In the first quarter of this year, Berkshire sold all of its remaining shares of two other pharma stocks -- AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). 10 stocks we like better t... |
23,162 | 2022-08-25 00:00:00 UTC | Annovis Bio (ANVS) Begins Dosing in Phase III Parkinson's Study | ABBV | https://www.nasdaq.com/articles/annovis-bio-anvs-begins-dosing-in-phase-iii-parkinsons-study | null | null | Annovis Bio ANVS announced the dosing of the first patient in a phase III study evaluating the company’s lead candidate, buntanetap, for the treatment of Parkinson’s Disease (PD).
The company announced top-line data from its phase IIa study of buntanetap in PD patients, treated with multiple-dose cohorts (5mg, 10mg, 20... | In May, Pharma giant AbbVie ABBV submitted a new drug application to the FDA for ABBV-951 (foscarbidopa/foslevodopa) for treating motor fluctuations in patients with advanced PD. AbbVie’s ABBV-951 has been designed to offer the first continuous subcutaneous delivery of carbidopa/levodopa (CD/LD) prodrugs for PD patient... | In May, Pharma giant AbbVie ABBV submitted a new drug application to the FDA for ABBV-951 (foscarbidopa/foslevodopa) for treating motor fluctuations in patients with advanced PD. AbbVie’s ABBV-951 has been designed to offer the first continuous subcutaneous delivery of carbidopa/levodopa (CD/LD) prodrugs for PD patient... | In May, Pharma giant AbbVie ABBV submitted a new drug application to the FDA for ABBV-951 (foscarbidopa/foslevodopa) for treating motor fluctuations in patients with advanced PD. AbbVie’s ABBV-951 has been designed to offer the first continuous subcutaneous delivery of carbidopa/levodopa (CD/LD) prodrugs for PD patient... | In May, Pharma giant AbbVie ABBV submitted a new drug application to the FDA for ABBV-951 (foscarbidopa/foslevodopa) for treating motor fluctuations in patients with advanced PD. AbbVie’s ABBV-951 has been designed to offer the first continuous subcutaneous delivery of carbidopa/levodopa (CD/LD) prodrugs for PD patient... |
23,163 | 2022-08-25 00:00:00 UTC | AbbVie (ABBV), J&J's Imbruvica Gets FDA Nod for cGVHD in Kids | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-jjs-imbruvica-gets-fda-nod-for-cgvhd-in-kids | null | null | AbbVie ABBV and partner J&J JNJ announced that Imbruvica, their blockbuster BTK inhibitor (BTKi) drug, has received label expansion approval from the FDA to treat chronic graft versus host disease (cGVHD) in pediatric patients.
The FDA granted approval to use Imbruvica in pediatric patients aged one year and older who ... | AbbVie ABBV and partner J&J JNJ announced that Imbruvica, their blockbuster BTK inhibitor (BTKi) drug, has received label expansion approval from the FDA to treat chronic graft versus host disease (cGVHD) in pediatric patients. Please note that this is the 12th FDA approval secured by both AbbVie and J&J for Imbruvica.... | AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Johnson & Johnson Price Johnson & Johnson price | Johnson & Johnson Quote Zacks Rank & Stocks to Consider AbbVie and J&J both currently carry a Zacks Rank #3 (Hold). AbbVie ABBV and partner J&J JNJ announced that Imbruvica, their blockbuster BTK inhibitor (BTKi) d... | AbbVie ABBV and partner J&J JNJ announced that Imbruvica, their blockbuster BTK inhibitor (BTKi) drug, has received label expansion approval from the FDA to treat chronic graft versus host disease (cGVHD) in pediatric patients. AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Johnson & Johnson Price Johnson & Jo... | AbbVie ABBV and partner J&J JNJ announced that Imbruvica, their blockbuster BTK inhibitor (BTKi) drug, has received label expansion approval from the FDA to treat chronic graft versus host disease (cGVHD) in pediatric patients. Please note that this is the 12th FDA approval secured by both AbbVie and J&J for Imbruvica.... |
23,164 | 2022-08-24 00:00:00 UTC | FDA Oks AbbVie' Imbruvica For Treatment Of Pediatric Patients With Chronic Graft Versus Host Disease | ABBV | https://www.nasdaq.com/articles/fda-oks-abbvie-imbruvica-for-treatment-of-pediatric-patients-with-chronic-graft-versus | null | null | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration approved the use of Imbruvica or ibrutinib for the treatment of pediatric patients one year and older with chronic graft versus host disease after failure of one or more lines of systemic therapy.
It is the first approved treatment option for chi... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration approved the use of Imbruvica or ibrutinib for the treatment of pediatric patients one year and older with chronic graft versus host disease after failure of one or more lines of systemic therapy. It is the first approved treatment option for chi... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration approved the use of Imbruvica or ibrutinib for the treatment of pediatric patients one year and older with chronic graft versus host disease after failure of one or more lines of systemic therapy. It is the first approved treatment option for chi... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration approved the use of Imbruvica or ibrutinib for the treatment of pediatric patients one year and older with chronic graft versus host disease after failure of one or more lines of systemic therapy. It is the first approved treatment option for chi... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration approved the use of Imbruvica or ibrutinib for the treatment of pediatric patients one year and older with chronic graft versus host disease after failure of one or more lines of systemic therapy. It is the first approved treatment option for chi... |
23,165 | 2022-08-24 00:00:00 UTC | Amgen (AMGN) Posts Positive Data from Soliris' Biosimilar Study | ABBV | https://www.nasdaq.com/articles/amgen-amgn-posts-positive-data-from-soliris-biosimilar-study | null | null | Amgen Inc. AMGN announced positive top-line data from the phase III study evaluating its biosimilar candidate, ABP 959, for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (“PNH”).
The DAHLIA study evaluated the safety and efficacy of ABP 959, a biosimilar candidate to Alexion’s [now part of As... | Humira, AbbVie’s flagship product is a key top driver for the company and the drug continues to witness strong demand trends in the United States. Key biosimilars in Amgen’s portfolio include Kanjinti (a biosimilar of Roche’s Herceptin) and Mvasi (biosimilar of Roche’s Avastin), Avsola (a biosimilar to J&J/Merck’s bloc... | Key biosimilars in Amgen’s portfolio include Kanjinti (a biosimilar of Roche’s Herceptin) and Mvasi (biosimilar of Roche’s Avastin), Avsola (a biosimilar to J&J/Merck’s blockbuster immunology medicine Remicade) and Amgevita (biosimilar of AbbVie’s ABBV Humira). Humira, AbbVie’s flagship product is a key top driver for ... | Key biosimilars in Amgen’s portfolio include Kanjinti (a biosimilar of Roche’s Herceptin) and Mvasi (biosimilar of Roche’s Avastin), Avsola (a biosimilar to J&J/Merck’s blockbuster immunology medicine Remicade) and Amgevita (biosimilar of AbbVie’s ABBV Humira). Humira, AbbVie’s flagship product is a key top driver for ... | Key biosimilars in Amgen’s portfolio include Kanjinti (a biosimilar of Roche’s Herceptin) and Mvasi (biosimilar of Roche’s Avastin), Avsola (a biosimilar to J&J/Merck’s blockbuster immunology medicine Remicade) and Amgevita (biosimilar of AbbVie’s ABBV Humira). Humira, AbbVie’s flagship product is a key top driver for ... |
23,166 | 2022-08-24 00:00:00 UTC | Top Stocks To Buy Now? 3 Dividend Paying Stocks To Watch Today | ABBV | https://www.nasdaq.com/articles/top-stocks-to-buy-now-3-dividend-paying-stocks-to-watch-today | null | null | Are These The Top Dividend Paying Stocks To Buy Right Now?
Dividend-paying stocks have long been a popular investment, offering both income and the potential for capital gains. While most stocks do not pay dividends, there are a number of companies that have chosen to distribute a portion of their profits to shareholde... | Dividend Paying Stocks To Buy [Or Avoid] Now AbbVie Inc. (NYSE: ABBV) Exxon Mobil Corporation (NYSE: XOM) International Business Machines Corporation (NYSE: IBM) AbbVie (NYSE: ABBV) AbbVie Inc is a pharmaceutical company that manufactures and markets branded pharmaceuticals, generic drugs, and over-the-counter products... | Dividend Paying Stocks To Buy [Or Avoid] Now AbbVie Inc. (NYSE: ABBV) Exxon Mobil Corporation (NYSE: XOM) International Business Machines Corporation (NYSE: IBM) AbbVie (NYSE: ABBV) AbbVie Inc is a pharmaceutical company that manufactures and markets branded pharmaceuticals, generic drugs, and over-the-counter products... | Dividend Paying Stocks To Buy [Or Avoid] Now AbbVie Inc. (NYSE: ABBV) Exxon Mobil Corporation (NYSE: XOM) International Business Machines Corporation (NYSE: IBM) AbbVie (NYSE: ABBV) AbbVie Inc is a pharmaceutical company that manufactures and markets branded pharmaceuticals, generic drugs, and over-the-counter products... | Dividend Paying Stocks To Buy [Or Avoid] Now AbbVie Inc. (NYSE: ABBV) Exxon Mobil Corporation (NYSE: XOM) International Business Machines Corporation (NYSE: IBM) AbbVie (NYSE: ABBV) AbbVie Inc is a pharmaceutical company that manufactures and markets branded pharmaceuticals, generic drugs, and over-the-counter products... |
23,167 | 2022-08-24 00:00:00 UTC | Want Passive Income? Invest In These 3 Dividend Kings | ABBV | https://www.nasdaq.com/articles/want-passive-income-invest-in-these-3-dividend-kings | null | null | Economic data has been mixed in recent weeks, which has led to an ongoing debate about whether the U.S. economy is in a recession. One side has the strong July jobs report to fall back on, while the other side can point to two consecutive quarters of negative gross domestic product growth. Ultimately, the official dete... | AbbVie Few items are as important to sustaining life than prescription medications, which is what makes AbbVie (NYSE: ABBV) about as recession-proof as a Dividend King could possibly be. Even though Humira's sales will drop quickly after its patent expires in 2023, AbbVie is well-prepared. In recent months, AbbVie has ... | See the 10 stocks *Stock Advisor returns as of August 17, 2022 Kody Kester has positions in AbbVie, Altria Group, and Genuine Parts Company. AbbVie Few items are as important to sustaining life than prescription medications, which is what makes AbbVie (NYSE: ABBV) about as recession-proof as a Dividend King could possi... | See the 10 stocks *Stock Advisor returns as of August 17, 2022 Kody Kester has positions in AbbVie, Altria Group, and Genuine Parts Company. AbbVie Few items are as important to sustaining life than prescription medications, which is what makes AbbVie (NYSE: ABBV) about as recession-proof as a Dividend King could possi... | See the 10 stocks *Stock Advisor returns as of August 17, 2022 Kody Kester has positions in AbbVie, Altria Group, and Genuine Parts Company. AbbVie Few items are as important to sustaining life than prescription medications, which is what makes AbbVie (NYSE: ABBV) about as recession-proof as a Dividend King could possi... |
23,168 | 2022-08-23 00:00:00 UTC | 7 Top-Rated Large-Cap Stocks to Buy and Hold | ABBV | https://www.nasdaq.com/articles/7-top-rated-large-cap-stocks-to-buy-and-hold-0 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Top-rated large-cap stocks can offer a bit of security in volatile times.
After the relief rally earlier this month, stocks may be in for another bout of weakness. Uncertainties like inflation, rising interest rates and a potential recession have still yet ... | ABBV AbbVie $140.34 ELV Elevance Health $507.00 GD General Dynamics $234.49 KO Coca-Cola $64.20 TSLA Tesla $869.74 UNH UnitedHealth Group $544.57 XOM ExxonMobil $94.01 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com As a major pharmaceutical company, AbbVie (NYSE:ABBV) is a great recession-resistant stock to includ... | ABBV AbbVie $140.34 ELV Elevance Health $507.00 GD General Dynamics $234.49 KO Coca-Cola $64.20 TSLA Tesla $869.74 UNH UnitedHealth Group $544.57 XOM ExxonMobil $94.01 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com As a major pharmaceutical company, AbbVie (NYSE:ABBV) is a great recession-resistant stock to includ... | ABBV AbbVie $140.34 ELV Elevance Health $507.00 GD General Dynamics $234.49 KO Coca-Cola $64.20 TSLA Tesla $869.74 UNH UnitedHealth Group $544.57 XOM ExxonMobil $94.01 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com As a major pharmaceutical company, AbbVie (NYSE:ABBV) is a great recession-resistant stock to includ... | ABBV AbbVie $140.34 ELV Elevance Health $507.00 GD General Dynamics $234.49 KO Coca-Cola $64.20 TSLA Tesla $869.74 UNH UnitedHealth Group $544.57 XOM ExxonMobil $94.01 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com As a major pharmaceutical company, AbbVie (NYSE:ABBV) is a great recession-resistant stock to includ... |
23,169 | 2022-08-22 00:00:00 UTC | The 7 Best Bargain Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/the-7-best-bargain-stocks-to-buy-now | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Given the unique circumstances associated with the Covid-19 pandemic, investors may want to take a step back from the crowd and consider the best bargain stocks to buy now. To be sure, several equity-based opportunities printed much red ink this year, prese... | Best Bargain Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com One of the more popular pharmaceutical companies, AbbVie (NYSE:ABBV) generated headlines prior to the Covid-19 pandemic with its acquisitiveness. In turn, the transaction would assign control to AbbVie for the highly profitable wrinkle treatment B... | Best Bargain Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com One of the more popular pharmaceutical companies, AbbVie (NYSE:ABBV) generated headlines prior to the Covid-19 pandemic with its acquisitiveness. In turn, the transaction would assign control to AbbVie for the highly profitable wrinkle treatment B... | Best Bargain Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com One of the more popular pharmaceutical companies, AbbVie (NYSE:ABBV) generated headlines prior to the Covid-19 pandemic with its acquisitiveness. In turn, the transaction would assign control to AbbVie for the highly profitable wrinkle treatment B... | Best Bargain Stocks: AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com One of the more popular pharmaceutical companies, AbbVie (NYSE:ABBV) generated headlines prior to the Covid-19 pandemic with its acquisitiveness. In turn, the transaction would assign control to AbbVie for the highly profitable wrinkle treatment B... |
23,170 | 2022-08-22 00:00:00 UTC | 2 Top Healthcare Stocks Defying the Bear Market | ABBV | https://www.nasdaq.com/articles/2-top-healthcare-stocks-defying-the-bear-market | null | null | It's been a terrible, horrible, no good, awful past seven months on Wall Street. Most companies are feeling the effects of macroeconomic headwinds such as inflation and supply chain issues, and few are managing to perform well on the market.
Thankfully, there are some companies in the black for the year. Two companies ... | Rinvoq and Skyrizi are well on their way to replacing AbbVie's crown jewel, immunosuppressant Humira, which may start facing generic competition in the U.S. sometime next year. And, of course, AbbVie boasts dozens of programs in development that should help it maintain a solid lineup and deal with patent cliffs as need... | Two companies in this group are AbbVie (NYSE: ABBV) and Jazz Pharmaceuticals (NASDAQ: JAZZ). ABBV data by YCharts 1. AbbVie AbbVie is a stable, blue-chip company that can deliver consistent revenue, profits, and growing dividends. | Two companies in this group are AbbVie (NYSE: ABBV) and Jazz Pharmaceuticals (NASDAQ: JAZZ). AbbVie AbbVie is a stable, blue-chip company that can deliver consistent revenue, profits, and growing dividends. In the second quarter, AbbVie's revenue increased by 4.5% year-over-year (YOY) to $14.6 billion. | Two companies in this group are AbbVie (NYSE: ABBV) and Jazz Pharmaceuticals (NASDAQ: JAZZ). AbbVie AbbVie is a stable, blue-chip company that can deliver consistent revenue, profits, and growing dividends. AbbVie's portfolio includes many products that are growing at a good clip. |
23,171 | 2022-08-22 00:00:00 UTC | FOCUS-Hiring and data: how the U.S. will set up new Medicare drug price talks | ABBV | https://www.nasdaq.com/articles/focus-hiring-and-data%3A-how-the-u.s.-will-set-up-new-medicare-drug-price-talks | null | null | By Ahmed Aboulenein
WASHINGTON, Aug 22 (Reuters) - The U.S. government will soon begin hiring experts and collecting the data needed to launch direct negotiations over prescription drug prices for older and disabled people, a top Biden administration official told Reuters.
President Joe Biden last week signed into law ... | Healthcare analysts have said that list could include Bristol-Myers Squibb Co's BMY.N top-selling cancer drug Revlimid, AbbVie Inc's ABBV.N rheumatoid arthritis drug Humira, and blood thinner pill Xarelto which is sold by Johnson & Johnson JNJ.N in the United States. President Joe Biden last week signed into law the In... | Healthcare analysts have said that list could include Bristol-Myers Squibb Co's BMY.N top-selling cancer drug Revlimid, AbbVie Inc's ABBV.N rheumatoid arthritis drug Humira, and blood thinner pill Xarelto which is sold by Johnson & Johnson JNJ.N in the United States. By Ahmed Aboulenein WASHINGTON, Aug 22 (Reuters) - T... | Healthcare analysts have said that list could include Bristol-Myers Squibb Co's BMY.N top-selling cancer drug Revlimid, AbbVie Inc's ABBV.N rheumatoid arthritis drug Humira, and blood thinner pill Xarelto which is sold by Johnson & Johnson JNJ.N in the United States. By Ahmed Aboulenein WASHINGTON, Aug 22 (Reuters) - T... | Healthcare analysts have said that list could include Bristol-Myers Squibb Co's BMY.N top-selling cancer drug Revlimid, AbbVie Inc's ABBV.N rheumatoid arthritis drug Humira, and blood thinner pill Xarelto which is sold by Johnson & Johnson JNJ.N in the United States. By Ahmed Aboulenein WASHINGTON, Aug 22 (Reuters) - T... |
23,172 | 2022-08-22 00:00:00 UTC | Five-Star Financial Blogger Zvi Bar is Bullish on These 2 Stocks | ABBV | https://www.nasdaq.com/articles/five-star-financial-blogger-zvi-bar-is-bullish-on-these-2-stocks | null | null | In our “Expert Spotlight” piece today, the TipRanks Expert Center brings top picks from notable financial blogger, Zvi Bar. Zvi Bar provides advisory services to companies, trusts, and individuals, including consulting expert services regarding retirement and estate planning. Moreover, he is a practicing lawyer in the ... | AbbVie Gets Endorsement from Bar Originating as a spin-off of Abbott Laboratories, AbbVie is a biopharmaceutical company established in 2013. He reckons that AbbVie’s high dividend yield of 3.9% and regular share repurchases make it an attractive choice for investors. Overall, 91% of bloggers on TipRanks are bullish on... | AbbVie Gets Endorsement from Bar Originating as a spin-off of Abbott Laboratories, AbbVie is a biopharmaceutical company established in 2013. He reckons that AbbVie’s high dividend yield of 3.9% and regular share repurchases make it an attractive choice for investors. Overall, 91% of bloggers on TipRanks are bullish on... | AbbVie Gets Endorsement from Bar Originating as a spin-off of Abbott Laboratories, AbbVie is a biopharmaceutical company established in 2013. He reckons that AbbVie’s high dividend yield of 3.9% and regular share repurchases make it an attractive choice for investors. Overall, 91% of bloggers on TipRanks are bullish on... | AbbVie Gets Endorsement from Bar Originating as a spin-off of Abbott Laboratories, AbbVie is a biopharmaceutical company established in 2013. He reckons that AbbVie’s high dividend yield of 3.9% and regular share repurchases make it an attractive choice for investors. Overall, 91% of bloggers on TipRanks are bullish on... |
23,173 | 2022-08-21 00:00:00 UTC | Which Growth Stock Is a Better Buy Right Now -- AbbVie or InMode? | ABBV | https://www.nasdaq.com/articles/which-growth-stock-is-a-better-buy-right-now-abbvie-or-inmode | null | null | The popularity of cosmetic procedures is unquestionably on the rise. Yet two major players in the space have seen their stocks struggle this year.
Major pharmaceutical AbbVie (NYSE: ABBV) is plagued by concerns about the impending patent cliff on its top-selling drug. At the same time, healthcare equipment provider InM... | The company's heavy reliance on a single drug creates shorter-term risk, but AbbVie has been diversifying its pharmaceutical and aesthetic offerings to shore up its long-term outlook. Major pharmaceutical AbbVie (NYSE: ABBV) is plagued by concerns about the impending patent cliff on its top-selling drug. The case for A... | AbbVie's aesthetics segment makes up a smaller portion of the portfolio, bringing in 9% of the company's $14.6 billion total second-quarter revenue. Major pharmaceutical AbbVie (NYSE: ABBV) is plagued by concerns about the impending patent cliff on its top-selling drug. The case for AbbVie AbbVie keeps a wary eye on th... | The case for AbbVie AbbVie keeps a wary eye on the calendar, with immunology megablockbuster Humira facing fierce biosimilar competition starting next year. Although AbbVie faces competition from other companies, Botox continues to capture the lion's share of the market with about 70% share. Major pharmaceutical AbbVie... | Major pharmaceutical AbbVie (NYSE: ABBV) is plagued by concerns about the impending patent cliff on its top-selling drug. The case for AbbVie AbbVie keeps a wary eye on the calendar, with immunology megablockbuster Humira facing fierce biosimilar competition starting next year. The question is whether AbbVie can mainta... |
23,174 | 2022-08-20 00:00:00 UTC | Bolster Your Social Security Benefits With These 2 Passive Income Stocks | ABBV | https://www.nasdaq.com/articles/bolster-your-social-security-benefits-with-these-2-passive-income-stocks | null | null | When you're investing to boost your Social Security income in retirement, it makes the most sense to invest in companies that are capable of performing consistently and paying out for years and years, so that you don't need to worry about managing your positions. In this vein, fast growth is less important than being a... | AbbVie AbbVie (NYSE: ABBV) develops new medicines for applications in immunology, neurology, cancer, and aesthetics, and it's also a dividend stock par excellence. And all of the above is more or less AbbVie's long-term norm, so it's a fairly stable business despite the ongoing need to develop new drugs and go through ... | AbbVie AbbVie (NYSE: ABBV) develops new medicines for applications in immunology, neurology, cancer, and aesthetics, and it's also a dividend stock par excellence. And all of the above is more or less AbbVie's long-term norm, so it's a fairly stable business despite the ongoing need to develop new drugs and go through ... | AbbVie AbbVie (NYSE: ABBV) develops new medicines for applications in immunology, neurology, cancer, and aesthetics, and it's also a dividend stock par excellence. And all of the above is more or less AbbVie's long-term norm, so it's a fairly stable business despite the ongoing need to develop new drugs and go through ... | AbbVie AbbVie (NYSE: ABBV) develops new medicines for applications in immunology, neurology, cancer, and aesthetics, and it's also a dividend stock par excellence. And all of the above is more or less AbbVie's long-term norm, so it's a fairly stable business despite the ongoing need to develop new drugs and go through ... |
23,175 | 2022-08-19 00:00:00 UTC | Friday's ETF with Unusual Volume: DVOL | ABBV | https://www.nasdaq.com/articles/fridays-etf-with-unusual-volume%3A-dvol | null | null | The First Trust Dorsey Wright Momentum & Low Volatility ETF is seeing unusually high volume in afternoon trading Friday, with over 197,000 shares traded versus three month average volume of about 26,000. Shares of DVOL were off about 0.2% on the day.
Components of that ETF with the highest volume on Friday were Procter... | Components of that ETF with the highest volume on Friday were Procter & Gamble, trading up about 0.5% with over 2.8 million shares changing hands so far this session, and Abbvie, up about 1.4% on volume of over 2.0 million shares. The First Trust Dorsey Wright Momentum & Low Volatility ETF is seeing unusually high volu... | Components of that ETF with the highest volume on Friday were Procter & Gamble, trading up about 0.5% with over 2.8 million shares changing hands so far this session, and Abbvie, up about 1.4% on volume of over 2.0 million shares. The First Trust Dorsey Wright Momentum & Low Volatility ETF is seeing unusually high volu... | Components of that ETF with the highest volume on Friday were Procter & Gamble, trading up about 0.5% with over 2.8 million shares changing hands so far this session, and Abbvie, up about 1.4% on volume of over 2.0 million shares. The First Trust Dorsey Wright Momentum & Low Volatility ETF is seeing unusually high volu... | Components of that ETF with the highest volume on Friday were Procter & Gamble, trading up about 0.5% with over 2.8 million shares changing hands so far this session, and Abbvie, up about 1.4% on volume of over 2.0 million shares. The First Trust Dorsey Wright Momentum & Low Volatility ETF is seeing unusually high volu... |
23,176 | 2022-08-19 00:00:00 UTC | Curis (CRIS) Lymphoma Study's Clinical Hold Lifted, Shares Gain | ABBV | https://www.nasdaq.com/articles/curis-cris-lymphoma-studys-clinical-hold-lifted-shares-gain | null | null | Curis CRIS shares were up 20% during market hours on Aug 18, after the company announced that the FDA has lifted the partial clinical hold on phase I/II TakeAim lymphoma study evaluating emavusertib (CA-4948) in patients with B-cell malignancies.
The open-label, dose-escalating phase I/II study is evaluating emavuserti... | The open-label, dose-escalating phase I/II study is evaluating emavusertib, an orally available IRAK4 kinase inhibitor, for treating patients with B-cell malignancies, both as a monotherapy and in combination with Johnson & Johnson JNJ / AbbVie’s ABBV BTK inhibitor, Imbruvica (ibrutinib)in patients with relapsed or ref... | The open-label, dose-escalating phase I/II study is evaluating emavusertib, an orally available IRAK4 kinase inhibitor, for treating patients with B-cell malignancies, both as a monotherapy and in combination with Johnson & Johnson JNJ / AbbVie’s ABBV BTK inhibitor, Imbruvica (ibrutinib)in patients with relapsed or ref... | The open-label, dose-escalating phase I/II study is evaluating emavusertib, an orally available IRAK4 kinase inhibitor, for treating patients with B-cell malignancies, both as a monotherapy and in combination with Johnson & Johnson JNJ / AbbVie’s ABBV BTK inhibitor, Imbruvica (ibrutinib)in patients with relapsed or ref... | The open-label, dose-escalating phase I/II study is evaluating emavusertib, an orally available IRAK4 kinase inhibitor, for treating patients with B-cell malignancies, both as a monotherapy and in combination with Johnson & Johnson JNJ / AbbVie’s ABBV BTK inhibitor, Imbruvica (ibrutinib)in patients with relapsed or ref... |
23,177 | 2022-08-18 00:00:00 UTC | Top Analyst Reports for JPMorgan Chase, AbbVie & Abbott | ABBV | https://www.nasdaq.com/articles/top-analyst-reports-for-jpmorgan-chase-abbvie-abbott | null | null | Thursday, August 18, 2022
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including JPMorgan Chase & Co. (JPM), AbbVie Inc. (ABBV) and Abbott Laboratories (ABT). These research reports have been hand-picked from the... | (You can read the full research report on JPMorgan Chase here >>>) AbbVie shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+24.0% vs. +4.9%), reflecting the company's successful label expansion of its cancer drugs, Imbruvica and Venclexta. If you want an email notification each ... | Today's Research Daily features new research reports on 12 major stocks, including JPMorgan Chase & Co. (JPM), AbbVie Inc. (ABBV) and Abbott Laboratories (ABT). If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Higher Rates to Aid JPMorgan (JPM) Margins, ... | (You can read the full research report on AbbVie here >>>) Abbott shares have declined -11.7% over the past year against the Zacks Medical - Products industry’s decline of -44.5%. If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Higher Rates to Aid JPMor... | Allergan’s acquisition has diversified AbbVie’s revenue base into new therapeutic areas, enhancing its long-term growth potential. Today's Research Daily features new research reports on 12 major stocks, including JPMorgan Chase & Co. (JPM), AbbVie Inc. (ABBV) and Abbott Laboratories (ABT). (You can read the full resea... |
23,178 | 2022-08-18 00:00:00 UTC | I-Mab (IMAB) Down After Partner AbbVie Revises Partnership Deal | ABBV | https://www.nasdaq.com/articles/i-mab-imab-down-after-partner-abbvie-revises-partnership-deal | null | null | Shares of I-Mab IMAB were down 14.3% on Aug 17 after management disclosed in an SEC filing that the company’s partner AbbVie ABBV has decided to discontinue a phase Ib study evaluating lemzoparlimab, its anti-CD47 antibody, in myelodysplastic syndrome (MDS) and acute myelocytic leukemia (AML) indications.
Though the re... | Shares of I-Mab IMAB were down 14.3% on Aug 17 after management disclosed in an SEC filing that the company’s partner AbbVie ABBV has decided to discontinue a phase Ib study evaluating lemzoparlimab, its anti-CD47 antibody, in myelodysplastic syndrome (MDS) and acute myelocytic leukemia (AML) indications. Though the re... | Shares of I-Mab IMAB were down 14.3% on Aug 17 after management disclosed in an SEC filing that the company’s partner AbbVie ABBV has decided to discontinue a phase Ib study evaluating lemzoparlimab, its anti-CD47 antibody, in myelodysplastic syndrome (MDS) and acute myelocytic leukemia (AML) indications. Though the re... | Shares of I-Mab IMAB were down 14.3% on Aug 17 after management disclosed in an SEC filing that the company’s partner AbbVie ABBV has decided to discontinue a phase Ib study evaluating lemzoparlimab, its anti-CD47 antibody, in myelodysplastic syndrome (MDS) and acute myelocytic leukemia (AML) indications. Though the re... | Shares of I-Mab IMAB were down 14.3% on Aug 17 after management disclosed in an SEC filing that the company’s partner AbbVie ABBV has decided to discontinue a phase Ib study evaluating lemzoparlimab, its anti-CD47 antibody, in myelodysplastic syndrome (MDS) and acute myelocytic leukemia (AML) indications. Though the re... |
23,179 | 2022-08-18 00:00:00 UTC | 3 Top Dividend Kings to Buy for the Long Haul | ABBV | https://www.nasdaq.com/articles/3-top-dividend-kings-to-buy-for-the-long-haul-2 | null | null | If you're hunting for stocks that you can expect to keep hiking their dividends year after year, look no further than the Dividend Kings. Every member of this elite group has a history of raising dividend payments year after year without interruption for at least 50 years, and many of the businesses are eager to do the... | Because its drugs eventually lose their exclusivity protections, opening the door for generics to steal their market share, AbbVie can't rest on its laurels or expect to develop a base of revenue that's safe in the long term. AbbVie AbbVie (NYSE: ABBV) is a pharmaceutical company that develops and sells medicines, and ... | AbbVie AbbVie (NYSE: ABBV) is a pharmaceutical company that develops and sells medicines, and it's a spin-off of Abbott Laboratories. Because its drugs eventually lose their exclusivity protections, opening the door for generics to steal their market share, AbbVie can't rest on its laurels or expect to develop a base o... | AbbVie AbbVie (NYSE: ABBV) is a pharmaceutical company that develops and sells medicines, and it's a spin-off of Abbott Laboratories. Because its drugs eventually lose their exclusivity protections, opening the door for generics to steal their market share, AbbVie can't rest on its laurels or expect to develop a base o... | AbbVie AbbVie (NYSE: ABBV) is a pharmaceutical company that develops and sells medicines, and it's a spin-off of Abbott Laboratories. Because its drugs eventually lose their exclusivity protections, opening the door for generics to steal their market share, AbbVie can't rest on its laurels or expect to develop a base o... |
23,180 | 2022-08-18 00:00:00 UTC | Do Options Traders Know Something About AbbVie (ABBV) Stock We Don't? | ABBV | https://www.nasdaq.com/articles/do-options-traders-know-something-about-abbvie-abbv-stock-we-dont | null | null | Investors in AbbVie Inc. ABBV need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 19, 2022 $75.00 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is ex... | Investors in AbbVie Inc. ABBV need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for AbbVie shares, but what is the fundamental picture for the company? Currently, AbbVie is a Zacks Rank #3 (Hold) in the Large Cap Pharmaceuticals indu... | AbbVie Inc. (ABBV): Free Stock Analysis Report Investors in AbbVie Inc. ABBV need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for AbbVie shares, but what is the fundamental picture for the company? | Given the way analysts feel about AbbVie right now, this huge implied volatility could mean there’s a trade developing. Investors in AbbVie Inc. ABBV need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for AbbVie shares, but what is th... | Given the way analysts feel about AbbVie right now, this huge implied volatility could mean there’s a trade developing. Investors in AbbVie Inc. ABBV need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for AbbVie shares, but what is th... |
23,181 | 2022-08-18 00:00:00 UTC | AbbVie (ABBV) Outperforms Industry This Year So Far: Here's Why | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-outperforms-industry-this-year-so-far%3A-heres-why | null | null | AbbVie ABBV stock has risen 4.4% this year so far compared with an increase of 0.5% for the industry.
Image Source: Zacks Investment Research
AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal has transformed Abb... | Image Source: Zacks Investment Research AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal has transformed AbbVie’s portfolio by lowering its dependence on Humira, its flagship product, which has already lost paten... | AbbVie Inc. (ABBV): Free Stock Analysis Report AbbVie ABBV stock has risen 4.4% this year so far compared with an increase of 0.5% for the industry. Image Source: Zacks Investment Research AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 bill... | Though Juvederm’s sales declined 15.7% in the second quarter due to the impact of COVID in China as well as the suspension of AbbVie’s aesthetics business operations in Russia, a key market for fillers, AbbVie expects sales to improve in the second half, gaining from lessening COVID impact and two new filler launches i... | Among AbbVie’s other immunology medicines, Skyrizi and Rinvoq are going strong, bolstered by approval in new indications. AbbVie and Roche jointly commercialize Venclexta in the United States while AbbVie markets it outside the country. AbbVie ABBV stock has risen 4.4% this year so far compared with an increase of 0.5%... |
23,182 | 2022-08-17 00:00:00 UTC | Those who invested in AbbVie (NYSE:ABBV) three years ago are up 148% | ABBV | https://www.nasdaq.com/articles/those-who-invested-in-abbvie-nyse%3Aabbv-three-years-ago-are-up-148 | null | null | The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company that is really flourishing, you can make more than 100%. To wit, the AbbVie Inc. (NYSE:ABBV) share price has flown 115% in the last three years. That sort of return is as solid as granite. In the last... | NYSE:ABBV Earnings Per Share Growth August 17th 2022 It is of course excellent to see how AbbVie has grown profits over the years, but the future is more important for shareholders. To wit, the AbbVie Inc. (NYSE:ABBV) share price has flown 115% in the last three years. AbbVie was able to grow its EPS at 37% per year ov... | To wit, the AbbVie Inc. (NYSE:ABBV) share price has flown 115% in the last three years. AbbVie was able to grow its EPS at 37% per year over three years, sending the share price higher. NYSE:ABBV Earnings Per Share Growth August 17th 2022 It is of course excellent to see how AbbVie has grown profits over the years, but... | To wit, the AbbVie Inc. (NYSE:ABBV) share price has flown 115% in the last three years. AbbVie was able to grow its EPS at 37% per year over three years, sending the share price higher. NYSE:ABBV Earnings Per Share Growth August 17th 2022 It is of course excellent to see how AbbVie has grown profits over the years, but... | To wit, the AbbVie Inc. (NYSE:ABBV) share price has flown 115% in the last three years. AbbVie was able to grow its EPS at 37% per year over three years, sending the share price higher. NYSE:ABBV Earnings Per Share Growth August 17th 2022 It is of course excellent to see how AbbVie has grown profits over the years, but... |
23,183 | 2022-08-16 00:00:00 UTC | Roche's (RHHBY) sBLA For Polivy Combo Accepted by FDA | ABBV | https://www.nasdaq.com/articles/roches-rhhby-sbla-for-polivy-combo-accepted-by-fda | null | null | Roche RHHBY announced that the FDA accepted its supplemental biologics license application (sBLA). The application seeks approval for its lymphoma drug Polivy (polatuzumab vedotin) in combination with Rituxan (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for treating adult patients with previous... | Roche’s hematology portfolio comprises of approved drugs like MabThera/Rituxan, Gazyva, Hemlibra (for hemophilia A with factor VIII inhibitors) and Venclexta (for acute myeloid leukemia in adults), being developed in collaboration with AbbVie ABBV. Venclexta is jointly commercialized by Genetech, a subsidiary of Roche ... | Roche’s hematology portfolio comprises of approved drugs like MabThera/Rituxan, Gazyva, Hemlibra (for hemophilia A with factor VIII inhibitors) and Venclexta (for acute myeloid leukemia in adults), being developed in collaboration with AbbVie ABBV. Venclexta is jointly commercialized by Genetech, a subsidiary of Roche ... | Roche’s hematology portfolio comprises of approved drugs like MabThera/Rituxan, Gazyva, Hemlibra (for hemophilia A with factor VIII inhibitors) and Venclexta (for acute myeloid leukemia in adults), being developed in collaboration with AbbVie ABBV. Venclexta is jointly commercialized by Genetech, a subsidiary of Roche ... | Roche’s hematology portfolio comprises of approved drugs like MabThera/Rituxan, Gazyva, Hemlibra (for hemophilia A with factor VIII inhibitors) and Venclexta (for acute myeloid leukemia in adults), being developed in collaboration with AbbVie ABBV. Venclexta is jointly commercialized by Genetech, a subsidiary of Roche ... |
23,184 | 2022-08-12 00:00:00 UTC | Noteworthy Friday Option Activity: SGEN, ABBV, BAC | ABBV | https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-sgen-abbv-bac | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Seagen Inc (Symbol: SGEN), where a total of 6,124 contracts have traded so far, representing approximately 612,400 underlying shares. That amounts to about 68.8% of SGEN's average daily trading volume over the p... | Particularly high volume was seen for the $143 strike call option expiring August 12, 2022, with 14,789 contracts trading so far today, representing approximately 1.5 million underlying shares of ABBV. Below is a chart showing SGEN's trailing twelve month trading history, with the $180 strike highlighted in orange: Abb... | Below is a chart showing SGEN's trailing twelve month trading history, with the $180 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 37,584 contracts thus far today. Particularly high volume was seen for the $143 strike call option expiring August 12, 2022, with 14,789 contracts ... | Particularly high volume was seen for the $143 strike call option expiring August 12, 2022, with 14,789 contracts trading so far today, representing approximately 1.5 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $143 strike highlighted in orange: And... | Below is a chart showing ABBV's trailing twelve month trading history, with the $143 strike highlighted in orange: And Bank of America Corp (Symbol: BAC) saw options trading volume of 246,107 contracts, representing approximately 24.6 million underlying shares or approximately 61.2% of BAC's average daily trading volum... |
23,185 | 2022-08-12 00:00:00 UTC | Notable ETF Outflow Detected - HDV, ABBV, IBM, PXD | ABBV | https://www.nasdaq.com/articles/notable-etf-outflow-detected-hdv-abbv-ibm-pxd | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core High Dividend ETF (Symbol: HDV) where we have detected an approximate $119.7 million dollar outflow -- that's a 0.9% decrease week over week (from 121,400,000 to 120,250,000). A... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.9%, International Business Machines Corp (Symbol: IBM) is up about 0.1%, and Pioneer Natural Resources Co (Symbol: PXD) is up by about 0.1%. For a complete list of holdings, visit the HDV Holdings page » The chart ... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.9%, International Business Machines Corp (Symbol: IBM) is up about 0.1%, and Pioneer Natural Resources Co (Symbol: PXD) is up by about 0.1%. For a complete list of holdings, visit the HDV Holdings page » The chart ... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.9%, International Business Machines Corp (Symbol: IBM) is up about 0.1%, and Pioneer Natural Resources Co (Symbol: PXD) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the univ... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.9%, International Business Machines Corp (Symbol: IBM) is up about 0.1%, and Pioneer Natural Resources Co (Symbol: PXD) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the univ... |
23,186 | 2022-08-12 00:00:00 UTC | See Which Of The Latest 13F Filers Holds AbbVie | ABBV | https://www.nasdaq.com/articles/see-which-of-the-latest-13f-filers-holds-abbvie-2 | null | null | At Holdings Channel, we have reviewed the latest batch of the 66 most recent 13F filings for the 06/30/2022 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 27 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed... | At Holdings Channel, we have reviewed the latest batch of the 66 most recent 13F filings for the 06/30/2022 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 27 of these funds. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the ... | At Holdings Channel, we have reviewed the latest batch of the 66 most recent 13F filings for the 06/30/2022 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 27 of these funds. Existing +1,148 +$154 DRW Securities LLC Existing -5,756 -$956 Wimmer Associates 1 LLC Existing -167 -$181 HCR Wealth Ad... | Existing +1,148 +$154 DRW Securities LLC Existing -5,756 -$956 Wimmer Associates 1 LLC Existing -167 -$181 HCR Wealth Advisors Existing -284 -$203 Financial Advocates Investment Management Existing +3,166 +$217 Corient Capital Partners LLC Existing +191 -$829 Birchcreek Wealth Management LLC Existing +528 +$67 ELCO Man... | At Holdings Channel, we have reviewed the latest batch of the 66 most recent 13F filings for the 06/30/2022 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 27 of these funds. UBS Group AG 9,752,330 4-10 Find out the full Top 10 Hedge Funds Holding ABBV » We'll keep following the latest 13F fili... |
23,187 | 2022-08-11 00:00:00 UTC | Senate Finance Committee looks at Amgen taxes, widening drugmaker probe | ABBV | https://www.nasdaq.com/articles/senate-finance-committee-looks-at-amgen-taxes-widening-drugmaker-probe | null | null | By Michael Erman
NEW YORK, Aug 11 (Reuters) - The U.S. Senate Finance Committee is widening its investigation into the tax practices of U.S. drugmakers to include Amgen Inc AMGN.O, according to a letter sent on Thursday by the committee's chairman, Senator Ron Wyden.
Amgen is already in the crosshairs of the U.S. Inter... | Wyden, a Democrat from Oregon, and his committee have been looking into how the tax law passed by Republicans in 2017 has benefited large U.S. drugmakers like Amgen, Merck and AbbVie, and whether those companies have been exploiting foreign subsidiaries to avoid taxes. Amgen is already in the crosshairs of the U.S. Int... | Wyden, a Democrat from Oregon, and his committee have been looking into how the tax law passed by Republicans in 2017 has benefited large U.S. drugmakers like Amgen, Merck and AbbVie, and whether those companies have been exploiting foreign subsidiaries to avoid taxes. "We can confirm that Amgen received a letter from ... | Wyden, a Democrat from Oregon, and his committee have been looking into how the tax law passed by Republicans in 2017 has benefited large U.S. drugmakers like Amgen, Merck and AbbVie, and whether those companies have been exploiting foreign subsidiaries to avoid taxes. By Michael Erman NEW YORK, Aug 11 (Reuters) - The ... | Wyden, a Democrat from Oregon, and his committee have been looking into how the tax law passed by Republicans in 2017 has benefited large U.S. drugmakers like Amgen, Merck and AbbVie, and whether those companies have been exploiting foreign subsidiaries to avoid taxes. By Michael Erman NEW YORK, Aug 11 (Reuters) - The ... |
23,188 | 2022-08-11 00:00:00 UTC | September 30th Options Now Available For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/september-30th-options-now-available-for-abbvie-abbv | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the September 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new September 30th contracts and identified one put and one call contract of particular interest.
The p... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $145.00 strike highlighted in red: Considering the fact that the $145.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $140.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $145.00 strike price has a current bid of $3.20. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new September 30th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $145.00 strike highlighted in red: Cons... |
23,189 | 2022-08-09 00:00:00 UTC | Few U.S. patients with hepatitis C get timely treatment, CDC says | ABBV | https://www.nasdaq.com/articles/few-u.s.-patients-with-hepatitis-c-get-timely-treatment-cdc-says | null | null | By Mrinalika Roy
Aug 9 (Reuters) - Few U.S. adults diagnosed with hepatitis C virus infections receive timely treatment with antiviral drugs, the U.S. Centers for Disease Control and Prevention said on Tuesday.
The drugs cure hepatitis C in more than 95% of patients, but a study of more than 47,000 adults diagnosed in ... | Several big pharma names including Gilead GILD.O, Bristol Myers SquibbBMY.N, and Abbvie ABBV.N have antiviral drugs in the market with prices ranging from $24,000 to $95,000 for a 12-week course. By Mrinalika Roy Aug 9 (Reuters) - Few U.S. adults diagnosed with hepatitis C virus infections receive timely treatment with... | Several big pharma names including Gilead GILD.O, Bristol Myers SquibbBMY.N, and Abbvie ABBV.N have antiviral drugs in the market with prices ranging from $24,000 to $95,000 for a 12-week course. By Mrinalika Roy Aug 9 (Reuters) - Few U.S. adults diagnosed with hepatitis C virus infections receive timely treatment with... | Several big pharma names including Gilead GILD.O, Bristol Myers SquibbBMY.N, and Abbvie ABBV.N have antiviral drugs in the market with prices ranging from $24,000 to $95,000 for a 12-week course. The drugs cure hepatitis C in more than 95% of patients, but a study of more than 47,000 adults diagnosed in 2019 or 2020 fo... | Several big pharma names including Gilead GILD.O, Bristol Myers SquibbBMY.N, and Abbvie ABBV.N have antiviral drugs in the market with prices ranging from $24,000 to $95,000 for a 12-week course. The drugs cure hepatitis C in more than 95% of patients, but a study of more than 47,000 adults diagnosed in 2019 or 2020 fo... |
23,190 | 2022-08-09 00:00:00 UTC | Reata (RETA) Q2 Earnings Miss, Revenues Down Y/Y, Stock Down | ABBV | https://www.nasdaq.com/articles/reata-reta-q2-earnings-miss-revenues-down-y-y-stock-down | null | null | Reata Pharmaceuticals, Inc. RETA reported a loss of $2.02 per share in second-quarter 2022, wider than the Zacks Consensus Estimate of a loss of $1.90.
However, the above loss included stock-based compensation and a non-cash interest expense. Adjusted loss for the quarter was $1.36 per share, wider than the loss of $1.... | Reata reacquired the development, manufacturing and commercialization rights for omaveloxolone and bardoxolone from AbbVie ABBV in 2019. The company also reacquired ex-U.S. rights to bardoxolone, omaveloxolone and its proprietary Nrf2 product platform from AbbVie during the same time. With this move, Reata is likely to... | Reata reacquired the development, manufacturing and commercialization rights for omaveloxolone and bardoxolone from AbbVie ABBV in 2019. The company also reacquired ex-U.S. rights to bardoxolone, omaveloxolone and its proprietary Nrf2 product platform from AbbVie during the same time. With this move, Reata is likely to... | Reata reacquired the development, manufacturing and commercialization rights for omaveloxolone and bardoxolone from AbbVie ABBV in 2019. The company also reacquired ex-U.S. rights to bardoxolone, omaveloxolone and its proprietary Nrf2 product platform from AbbVie during the same time. With this move, Reata is likely to... | Reata reacquired the development, manufacturing and commercialization rights for omaveloxolone and bardoxolone from AbbVie ABBV in 2019. The company also reacquired ex-U.S. rights to bardoxolone, omaveloxolone and its proprietary Nrf2 product platform from AbbVie during the same time. With this move, Reata is likely to... |
23,191 | 2022-08-08 00:00:00 UTC | Should You Buy Merck Stock After An Upbeat Q2? | ABBV | https://www.nasdaq.com/articles/should-you-buy-merck-stock-after-an-upbeat-q2 | null | null | Merck stock (NYSE: MRK) reported its Q2 results last week, with revenue and earnings comfortably above ours and the street estimates. However, MRK stock has seen a fall of around 4% in a week, with rising concerns over the drug pricing bill. After the recent fall, we believe MRK stock has some more room for growth and ... | Seagen’s key products are Padcev, Tukysa, and Adcetris, each a potential blockbuster drug that can help Merck post more robust revenue growth. We estimate Merck’s valuation of $102 per share, reflecting a 15% upside from its current market price near $88, implying that investors may be better off using the recent dip ... | At its current levels, MRK stock is trading at under 12x its forward earnings, compared to the last three-year average of 13x, implying some more room for growth. We have allocated a slightly higher earnings multiple for Merck (compared to the levels seen in recent years) due to an expected rise in earnings over the co... | We estimate Merck’s valuation of $102 per share, reflecting a 15% upside from its current market price near $88, implying that investors may be better off using the recent dip to enter MRK stock for gains in the long run. We have allocated a slightly higher earnings multiple for Merck (compared to the levels seen in r... | This compares with our estimates of $13.9 billion and $1.73, respectively. We expect full-year 2022 revenue to be $58.0 billion, within the company’s provided range, but earnings to be $7.38, marginally higher than its estimates. We have allocated a slightly higher earnings multiple for Merck (compared to the levels se... |
23,192 | 2022-08-07 00:00:00 UTC | 3 Unstoppable Stocks That Don't Care About the Bear Market | ABBV | https://www.nasdaq.com/articles/3-unstoppable-stocks-that-dont-care-about-the-bear-market | null | null | Whether it's thanks to a winning business model or timely good news, some companies are taking the bear market in stride, and some are even crushing it.
In particular, there are three big pharma stocks that are rising higher amid the market's decline. If you're interested in building some all-weather growth into your p... | AbbVie Much like AstraZeneca, AbbVie (NYSE: ABBV) boasts a massive development pipeline that commonly has four or more programs awaiting rulings from regulators and dozens of late-stage programs in progress at the same time. AbbVie's performance during the bear market has been similarly strong, with the total return of... | Bristol Myers Squibb Bristol Myers Squibb's (NYSE: BMY) stock is up by 15% this year even though its pipeline isn't as jam-packed with looming approvals as AbbVie or AstraZeneca. AbbVie Much like AstraZeneca, AbbVie (NYSE: ABBV) boasts a massive development pipeline that commonly has four or more programs awaiting ruli... | Given that the medicine was responsible for bringing in more than $17.3 billion during 2021 out of AbbVie's net revenue of $56.1 billion, if its plans to replace the falling revenue with sales from new programs falters, the next couple of years could actually end up being more difficult for investors than the bear mark... | AbbVie's performance during the bear market has been similarly strong, with the total return of its shares increasing by 6% in comparison to the market's decline of 13% this year so far. Bristol Myers Squibb Bristol Myers Squibb's (NYSE: BMY) stock is up by 15% this year even though its pipeline isn't as jam-packed wit... |
23,193 | 2022-08-06 00:00:00 UTC | 3 Unstoppable Dividend Stocks to Buy in August | ABBV | https://www.nasdaq.com/articles/3-unstoppable-dividend-stocks-to-buy-in-august | null | null | Some dividend stocks are better than others. The differentiator is how strong the underlying businesses are that make the dividends possible.
We asked three Motley Fool contributors to pick unstoppable dividend stocks to buy in August. Here's why they chose AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Pfi... | Here's why they chose AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Pfizer (NYSE: PFE). Winning over the long term Keith Speights (AbbVie): If you only focused on the short term, you might turn up your nose at AbbVie. AbbVie also faces biosimilar competition in the U.S. for its top-selling drug, Humira, be... | Here's why they chose AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Pfizer (NYSE: PFE). Winning over the long term Keith Speights (AbbVie): If you only focused on the short term, you might turn up your nose at AbbVie. AbbVie also faces biosimilar competition in the U.S. for its top-selling drug, Humira, be... | AbbVie ranks as a Dividend King, with 50 consecutive years of dividend increases under its belt. Here's why they chose AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Pfizer (NYSE: PFE). Winning over the long term Keith Speights (AbbVie): If you only focused on the short term, you might turn up your nose at ... | Here's why they chose AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Pfizer (NYSE: PFE). Winning over the long term Keith Speights (AbbVie): If you only focused on the short term, you might turn up your nose at AbbVie. AbbVie also faces biosimilar competition in the U.S. for its top-selling drug, Humira, be... |
23,194 | 2022-08-05 00:00:00 UTC | 3 Reasons Why AbbVie Stock Could Be Approaching a Make or Break Moment | ABBV | https://www.nasdaq.com/articles/3-reasons-why-abbvie-stock-could-be-approaching-a-make-or-break-moment | null | null | After the market's tepid reception to AbbVie's (NYSE: ABBV) latest earnings report on July 29, the drugmaker appears to face a fork in the road ahead. Down one path is the potential decline of market share for its most profitable medicine and a further drop in the stock price. The other potential path is far sunnier wi... | After the market's tepid reception to AbbVie's (NYSE: ABBV) latest earnings report on July 29, the drugmaker appears to face a fork in the road ahead. Sales of Allergan's medicines have helped AbbVie continue to grow its top line even as revenue from its biggest moneymaker, the psoriatic arthritis drug Humira, has star... | Per AbbVie's Q2 earnings update, sales from aesthetics therapies dipped by 4.4% year-over-year on a reported basis as a result of Juvederm, which saw its revenue crash by 19.5% to $344 million. Revenue from Skyrizi and Rinvoq is ramping up rapidly The final reason why AbbVie is approaching a make or break point is that... | AbbVie's entire aesthetics segment is fairly modest, worth only $1.3 billion compared with the company's total revenue of about $14.5 billion, and AbbVie needs all the growth it can get. Revenue from Skyrizi and Rinvoq is ramping up rapidly The final reason why AbbVie is approaching a make or break point is that its st... | After the market's tepid reception to AbbVie's (NYSE: ABBV) latest earnings report on July 29, the drugmaker appears to face a fork in the road ahead. So which way will AbbVie's fortunes go? Its new aesthetics segment just stumbled The first reason AbbVie is approaching a critical point is that one of its engines of gr... |
23,195 | 2022-08-05 00:00:00 UTC | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know | ABBV | https://www.nasdaq.com/articles/investors-heavily-search-abbvie-inc.-abbv%3A-here-is-what-you-need-to-know-0 | null | null | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this drugmaker have returned -8.6%, compared to the Zacks S&P 500 composite's +8.7% change. During thi... | Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. During this period, the Zacks Large Cap Pharmaceuticals indust... | Last Reported Results and Surprise History AbbVie reported revenues of $14.58 billion in the last reported quarter, representing a year-over-year change of +4.5%. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVi... | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has lost 4.5%. For the current quarter, AbbVie is expected to post earnings of $3.59 per share, indicating a change of +7.8% from the year-ago quarter. | For the next fiscal year, the consensus earnings estimate of $11.80 indicates a change of -15.1% from what AbbVie is expected to report a year ago. AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, has... |
23,196 | 2022-08-05 00:00:00 UTC | Ironwood (IRWD) Q2 Earnings Miss, Keeps 2022 Sales Guidance | ABBV | https://www.nasdaq.com/articles/ironwood-irwd-q2-earnings-miss-keeps-2022-sales-guidance | null | null | Ironwood Pharmaceuticals, Inc. IRWD reported second-quarter 2022 adjusted earnings of 21 cents per share, missing the Zacks Consensus Estimate of 31 cents. The company had reported adjusted earnings of 34 cents per share in the year-ago quarter.
Total revenues of $97.2 million missed the Zacks Consensus Estimate of $99... | Image Source: Zacks Investment Research Quarter in Detail As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — generated net sales of almost $248.35 million in the United States, down 4.2% year over year. Ironwood and AbbVie equally share Linzess’ brand collaboration profits or... | Image Source: Zacks Investment Research Quarter in Detail As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — generated net sales of almost $248.35 million in the United States, down 4.2% year over year. Ironwood and AbbVie equally share Linzess’ brand collaboration profits or... | Image Source: Zacks Investment Research Quarter in Detail As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — generated net sales of almost $248.35 million in the United States, down 4.2% year over year. Ironwood and AbbVie equally share Linzess’ brand collaboration profits or... | Image Source: Zacks Investment Research Quarter in Detail As reported by partner AbbVie ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — generated net sales of almost $248.35 million in the United States, down 4.2% year over year. Ironwood and AbbVie equally share Linzess’ brand collaboration profits or... |
23,197 | 2022-08-04 00:00:00 UTC | Notable ETF Outflow Detected - AOR, ABBV, COST, ACN | ABBV | https://www.nasdaq.com/articles/notable-etf-outflow-detected-aor-abbv-cost-acn | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core Growth Allocation ETF (Symbol: AOR) where we have detected an approximate $77.5 million dollar outflow -- that's a 3.9% decrease week over week (from 40,000,000 to 38,450,000). ... | Among the largest underlying components of AOR, in trading today AbbVie Inc (Symbol: ABBV) is off about 1.2%, Costco Wholesale Corp (Symbol: COST) is off about 0.4%, and Accenture plc (Symbol: ACN) is lower by about 0.2%. For a complete list of holdings, visit the AOR Holdings page » The chart below shows the one year ... | Among the largest underlying components of AOR, in trading today AbbVie Inc (Symbol: ABBV) is off about 1.2%, Costco Wholesale Corp (Symbol: COST) is off about 0.4%, and Accenture plc (Symbol: ACN) is lower by about 0.2%. For a complete list of holdings, visit the AOR Holdings page » The chart below shows the one year ... | Among the largest underlying components of AOR, in trading today AbbVie Inc (Symbol: ABBV) is off about 1.2%, Costco Wholesale Corp (Symbol: COST) is off about 0.4%, and Accenture plc (Symbol: ACN) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at E... | Among the largest underlying components of AOR, in trading today AbbVie Inc (Symbol: ABBV) is off about 1.2%, Costco Wholesale Corp (Symbol: COST) is off about 0.4%, and Accenture plc (Symbol: ACN) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at E... |
23,198 | 2022-08-03 00:00:00 UTC | 7 Cheap Biotech Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/7-cheap-biotech-stocks-to-buy-now-0 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Biopharmaceutical companies have been struggling since 2021 and that narrative isn’t immediately changing. However, not every firm deserves this fate. In fact, investors can find great opportunities with “cheap” biotech stocks to buy now.
There are many rea... | It has an ongoing collaboration with AbbVie (NYSE:ABBV) for two CAR-T programs. The agreement between the companies also vests AbbVie with the option of adding two more programs. Apellis Pharma (NASDAQ:APLS) has a similar drug in its pipeline for the same indication and its regulatory application has been accepted for ... | It has an ongoing collaboration with AbbVie (NYSE:ABBV) for two CAR-T programs. The agreement between the companies also vests AbbVie with the option of adding two more programs. ACET Adicet Bio $17.50 ISEE IVERIC bio $11.45 KDNY Chinook Therapeutics $19.26 RCKT Rocket Pharmaceuticals $14.50 PLRX Pliant Therapeutics $1... | It has an ongoing collaboration with AbbVie (NYSE:ABBV) for two CAR-T programs. The agreement between the companies also vests AbbVie with the option of adding two more programs. ACET Adicet Bio $17.50 ISEE IVERIC bio $11.45 KDNY Chinook Therapeutics $19.26 RCKT Rocket Pharmaceuticals $14.50 PLRX Pliant Therapeutics $1... | It has an ongoing collaboration with AbbVie (NYSE:ABBV) for two CAR-T programs. The agreement between the companies also vests AbbVie with the option of adding two more programs. ACET Adicet Bio $17.50 ISEE IVERIC bio $11.45 KDNY Chinook Therapeutics $19.26 RCKT Rocket Pharmaceuticals $14.50 PLRX Pliant Therapeutics $1... |
23,199 | 2022-08-03 00:00:00 UTC | Famed "Big Short" Investor Loves This Multibillion-Dollar Company -- Should You? | ABBV | https://www.nasdaq.com/articles/famed-big-short-investor-loves-this-multibillion-dollar-company-should-you | null | null | Michael Burry rose to fame by calling the 2008 housing bubble, as documented in the hit movie The Big Short. More recently, he reentered the spotlight by buying into Gamestop before it became a meme stock. Taking a hard turn from such dramatic holdings, pharmaceutical stalwart Bristol Myers Squibb (NYSE: BMY) is now on... | Compare this to other healthcare behemoths AbbVie, Abbott, and Amgen, all of which have lower P/E ratios and have beaten the S&P over both the last 10 and 25 years, including dividends. With the initiation of several late-stage trials for Opdualag in large markets such as colorectal and lung cancer, it is clear that th... | Compare this to other healthcare behemoths AbbVie, Abbott, and Amgen, all of which have lower P/E ratios and have beaten the S&P over both the last 10 and 25 years, including dividends. One of these hopeful new compounds, cancer-fighting Opdualag, is a combination of Bristol's hit drug Opdivo and another monoclonal ant... | Compare this to other healthcare behemoths AbbVie, Abbott, and Amgen, all of which have lower P/E ratios and have beaten the S&P over both the last 10 and 25 years, including dividends. The phase 2 investigational drug milvexian is being evaluated to take over both the anti-platelet market -- think Plavix and its $7 bi... | Compare this to other healthcare behemoths AbbVie, Abbott, and Amgen, all of which have lower P/E ratios and have beaten the S&P over both the last 10 and 25 years, including dividends. A phase 2 study on a subset of heart failure patients is set to report results in April 2023, a market of just over 2 million patients... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.